Rak v Sloveniji Cancer in Slovenia annual report letno porocilo Rak v Sloveniji Cancer in Slovenia annual report letno porocilo Rak v Sloveniji Cancer in Slovenia 2017 Naslov Title Rak v Sloveniji 2017 / Cancer in Slovenia 2017 Uredniški odbor Editorial Board Vesna Zadnik, glavna urednica / editor-in-chief Gorana Gašljevic, Marko Hocevar, Urška Ivanuš, Katja Jarm, Vera Pompe-Kirn, Primož Strojan, Sonja Tomšic, Branko Zakotnik in Tina Žagar Racunalniška obdelava EDP Analysis Nika Bric, Tina Žagar, Katarina Lokar in Miran Mlakar Oblikovanje in priprava za tisk Design and Typesetting Nika Bric Tisk Printing Koštomaj d.o.o. Izdajatelj Published by Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, SloveniaEpidemiologija in register raka / Epidemiology and Cancer RegistryRegister raka Republike Slovenije / Slovenian Cancer Registry Naklada Published in 800 izvodov / 800 copies Nasvet za citiranje Recommended Reference Rak v Sloveniji 2017. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2020. Cancer in Slovenia 2017. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2020. Osebje Registra raka Republike Slovenije Staff of the Slovenian Cancer Registry Vesna Zadnik, vodja / head Agata Campa, Mojca Colnik, Maruška Ferjancic, Andrej Kirn, Andrej Krašovec, Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, Polona Rus, Darja Strle, Laura Šeneker Zupanc, Franciška Škrlec, Polona Škulj, Urška Tomšic, Boštjan Zavratnik, Brigita Zore, Nika Bric, Ana Mihor, Miran Mlakar, Katarina Lokar, Sonja Tomšic, Tina Žagar Naslov Correspondence to Register raka Republike Slovenije / Slovenian Cancer Registry Onkološki inštitut Ljubljana / Institute of Oncology LjubljanaZaloška c. 2, 1001 Ljubljana, p.p. 2217, SlovenijaTelefon / Phone: + 386 1 5879 450 E-pošta / E-mail: register@onko-i.si Spletna stran / Web site: http://www.onko-i.si/rrs/ http://www.slora.si/ http://www.onko-i.si/eng/crs/ http://www.slora.si/en/ Kazalo Contents3Kazalo Uvodnik 6 Editorial 7 Podatki 8 Viri podatkov 8 Obdelava podatkov 9 Kakovost podatkov 10 Data 12 Data Sources 12 Data Processing 13 Data Quality 14 Rak v Sloveniji 15 Osnovni podatki o raku v Sloveniji 2017 16 Starost bolnikov 16 Casovni trend 16 Najpogostejši raki 18 Trend najpogostejših rakov 21 Redki raki 22 Preživetje 23 Primerjava z Evropo 26 Cancer in Slovenia 28 Basic figures on cancer in Slovenia 2017 28 Age of patients 28 Time trends 29 Most frequent cancers 29 Time trends for most frequent cancers 29 Rare cancers 30 Survival 30 Comparisons with Europe 31 Incidenca Incidence 32 Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2008-2017 in 2020. 32 Table 1: Observed and estimated cancer incidence by sex, Slovenia 2008-2017 and 2020. 32 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2017. 33 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2017. 33 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2017. 34 Table 3: Cancer incidence by age and by sex with crude rate (CR) per 100,000 population and cumulative rate (CR), Slovenia 2017. 34 Contents 3Kazalo Uvodnik 6 Editorial 7 Podatki 8 Viri podatkov 8 Obdelava podatkov 9 Kakovost podatkov 10 Data 12 Data Sources 12 Data Processing 13 Data Quality 14 Rak v Sloveniji 15 Osnovni podatki o raku v Sloveniji 2017 16 Starost bolnikov 16 Casovni trend 16 Najpogostejši raki 18 Trend najpogostejših rakov 21 Redki raki 22 Preživetje 23 Primerjava z Evropo 26 Cancer in Slovenia 28 Basic figures on cancer in Slovenia 2017 28 Age of patients 28 Time trends 29 Most frequent cancers 29 Time trends for most frequent cancers 29 Rare cancers 30 Survival 30 Comparisons with Europe 31 Incidenca Incidence 32 Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2008-2017 in 2020. 32 Table 1: Observed and estimated cancer incidence by sex, Slovenia 2008-2017 and 2020. 32 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2017. 33 Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2017. 33 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2017. 34 Table 3: Cancer incidence by age and by sex with crude rate (CR) per 100,000 population and cumulative rate (CR), Slovenia 2017. 34 Contents Tabela 4a: Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2017. 38 Table 4a: Incidence of microscopicaly (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2017. 38 Tabela 4b: Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2017. 42 Table 4b: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2017. 42 Tabela 4c: Incidenca ne-Hodgkinovih limfomov po lokaciji, Slovenija 2017. 43 Table 4c: Incidence of non-Hodgkin´s malignant lymphomas by cancer site, Slovenia 2017. 43 Tabela 5: Incidenca raka po stadiju, Slovenija 2017. 44 Table 5: Cancer incidence by stage, Slovenia 2017. 44 Prevalenca Prevalence 46 Tabela 6: Prevalenca po spolu, Slovenija, 31. 12. 2017. 46 Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2017. 46 Umrljivost Mortality 47 Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2017. Vir: Nacionalni inštitut za javno zdravje 47 Table 7: Cancer mortality by age and by sex, Slovenia 2017. Source: National Institute of Public Health 47 Preživetje Survival 48 Tabela 8: Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2013–2017. 48 Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2013–2017 by sex. 48 Zdravljenje Treatment 49 Tabela 9a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). 49 Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). 49 Tabela 9b: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji bolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani*, po bolnici posega. 50 Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery during their first treatment* by treatment institution. 50 Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po bolnici zdravljenja. 51 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by systemic therapy during their first treatment* by treatment institution. 51 Breme najpogostejših rakov Cancer Fact Sheets 52 Vsi raki / All cancer sites (C00–C96) 52 Prostata / Prostate (C61) 53 Pljuca in sapnik / Lung and trachea (C33, C34) 54 Dojka / Breast (C50) 55 Debelo crevo in danka / Colon and rectum (C18–C20) 56 Koža, razen melanoma / Skin, non-melanoma (C44) 57 Kožni melanom / Malignant melanoma of skin (C43) 58 Glava in vrat / Head and neck (C00–C14, C30–C32) 59 Maternicno telo / Corpus uteri (C54) 60 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) 61 Pojmovnik 62 Glossary 63 Uvodnik 6UvodnikRegister raka Republike Slovenije je v svetovnem merilu prepoznan kot eden najstarejših in najkvalite- tnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od zacetka deluje v okviru Onkološkega inštituta Ljubljana. Zacetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporocili Svetovne zdravstvene organizacije zavedala, da je uspešnost in ucinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoce objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v casu. Letos praznujemo 70. letnico neprekinjenega delovanja slovenskega Registra raka. Castitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani www.onko-i.si/rrs ter v posebej za to priložnost izdani brošuri. Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so sku- paj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za oce- njevanje bremena rakavih bolezni v državi. Pomembni so za nacrtovanje in ocenjevanje Državnega programa obvladovanja raka na podrocju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za nacrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolez- ni (osebje, medicinska oprema, bolnišnicne zmogljivosti). Dragoceni so za klinicne in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje ucinkovitosti presejalnih programov. Z natancnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru klinicnih registrov, pa lahko, poleg zgoraj opisanega, spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišnicnega registra Onkološkega inštituta Ljubljana, ki že ves cas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogocajo podrobnejši pregled nad bolniki, zdravljenimi na Inštitutu. Redna letna porocila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben cas za izdajo letnega porocila nekoliko daljši, v po- rocilih zadnja leta objavimo tudi pricakovano incidenco raka v letu, ko je porocilo izdano (v tokratnem porocilu za leto 2020). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga poimenovali SLORA po zacetnih crkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora. si. Omogoca preprost in hiter dostop do vecine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoca primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in svetu. Vsem, ki so kakorkoli prispevali k izdaji tega porocila, tako sodelavcem Registra raka, kot tudi vsem zdravnikom in klinicnemu osebju po vsej državi, ki ste nam posredovali porocila o diagnozi in zdra- vljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem. prof. dr. Vesna Zadnik, dr. med. vodja Registra raka Republike SlovenijeLjubljana, september 2020 6UvodnikRegister raka Republike Slovenije je v svetovnem merilu prepoznan kot eden najstarejših in najkvalite- tnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od zacetka deluje v okviru Onkološkega inštituta Ljubljana. Zacetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporocili Svetovne zdravstvene organizacije zavedala, da je uspešnost in ucinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoce objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v casu. Letos praznujemo 70. letnico neprekinjenega delovanja slovenskega Registra raka. Castitljivo obletnico smo obeležili tudi s pripravo zgodovinskega pregleda delovanja Registra v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazane na naši spletni strani www.onko-i.si/rrs ter v posebej za to priložnost izdani brošuri. Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so sku- paj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za oce- njevanje bremena rakavih bolezni v državi. Pomembni so za nacrtovanje in ocenjevanje Državnega programa obvladovanja raka na podrocju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za nacrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolez- ni (osebje, medicinska oprema, bolnišnicne zmogljivosti). Dragoceni so za klinicne in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje ucinkovitosti presejalnih programov. Z natancnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v okviru klinicnih registrov, pa lahko, poleg zgoraj opisanega, spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišnicnega registra Onkološkega inštituta Ljubljana, ki že ves cas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogocajo podrobnejši pregled nad bolniki, zdravljenimi na Inštitutu. Redna letna porocila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben cas za izdajo letnega porocila nekoliko daljši, v po- rocilih zadnja leta objavimo tudi pricakovano incidenco raka v letu, ko je porocilo izdano (v tokratnem porocilu za leto 2020). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga poimenovali SLORA po zacetnih crkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora. si. Omogoca preprost in hiter dostop do vecine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoca primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in svetu. Vsem, ki so kakorkoli prispevali k izdaji tega porocila, tako sodelavcem Registra raka, kot tudi vsem zdravnikom in klinicnemu osebju po vsej državi, ki ste nam posredovali porocila o diagnozi in zdra- vljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem. prof. dr. Vesna Zadnik, dr. med. vodja Registra raka Republike SlovenijeLjubljana, september 2020 Editorial The Slovenian Cancer Registry is recognized as one of the oldest and best quality population-based cancer registries in Europe and the world. Founded in 1950, from the very beginning it has operated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, Prof Dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. This year we are celebrating the 70th anniversary of continuous operation at the Slovenian Cancer Registry. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Register in all these years. Readers interested in learning more can find historical facts and anecdotes on our website www.onko-i.si/rrs and in a brochure published especially for this occasion. Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, together with mortality data collected and processed by the National Institute of Public Health, are the basis for assessing the burden of cancer in the country. The Registry’s data are important for the planning and evaluation of the National Cancer Control Programme for primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as in planning regarding facilities and resources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research, and for evaluating the effectiveness of screening programmes. In addition to all this, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment oncology patients receive. Data of the Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nation-wide Cancer Registry and in large part also supplied with data via the Registry, provides a more detailed overview of patients treated at the Institute. Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional community and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, in recent years we have started to include in the report the projected cancer incidence for the year when the report is issued (i.e. for 2020 in this report). Since 2010, our SLORA interactive web portal – www.slora.si – has also been up and running; it is named based on the initial letters of the words »Slovenia and cancer [rak]«. It provides easy and quick access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of the cancer burden in Slovenia with other countries in Europe and the world. On behalf of the Editorial Board, I would like to sincerely thank everyone who has contrpublication of this report, including the staff at the Cancer Registry along with alclinical staff across the country who have provided us with reports on cancer di ibuted to the l the physicians and agnosis and treatment. prof. Vesna Zadnik, MD, PhD Ljubljana, September 2020 director of the Slovenian Cancer Registry Podatki8PodatkiViri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vkljucevanjem razlicnih vi- rov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju razlicnih zbirk se uporablja enotni državni identifikator EMŠO. Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdra- vijo in spremljajo. Tradicionalno bolnišnice porocajo Registru raka na posebnem formularju Prijavnici rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Kliniki Golnik zbirajo podatke za Prijavnico v lastnem bolnišnicnem registru ter jih v Register raka od tam posredujejo elektronsko; v ostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo ali od njih pooblašceno osebje. Skladno s cilji Državnega programa obvladovanja raka 2017-2021 smo v letu 2019 zaceli uvaja- ti tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Re- gistru raka posredujejo seznam bolnikov ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno porocanje prek Prijavnic je tako ukinjeno. Za zbolele v letu 2017, ki so prikazani v tem porocilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem klinicnem centru Maribor, Pediatricni kliniki ter Klinicnem oddelku za hematologijo Univerzitetnega klinicnega centra Ljubljana. Dopolnilni vir podatkov Registra raka so zdravniška porocila o vzroku smrti, ki nam jih pošilja Nacio- nalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na mater- nicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem crevesu in danki. Za izracun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne analize Državne zdravstvene podatkovne zbirke: - Register umrlihUpravniregistri: - CRP- GURS Presejalni programi: - ZORA- Svit- DORA Javno- zdravstveni zavodi: - Pasivna ali aktivna prijava Bolnišnicni register: - OIL- Golnik Klinicne in populacijske raziskave REGISTERRAKA RS 8PodatkiViri podatkov Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vkljucevanjem razlicnih vi- rov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju razlicnih zbirk se uporablja enotni državni identifikator EMŠO. Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdra- vijo in spremljajo. Tradicionalno bolnišnice porocajo Registru raka na posebnem formularju Prijavnici rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Kliniki Golnik zbirajo podatke za Prijavnico v lastnem bolnišnicnem registru ter jih v Register raka od tam posredujejo elektronsko; v ostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo ali od njih pooblašceno osebje. Skladno s cilji Državnega programa obvladovanja raka 2017-2021 smo v letu 2019 zaceli uvaja- ti tako imenovano aktivno registracijo, kjer bolnišnice v svojih informacijskih sistemih pripravijo in Re- gistru raka posredujejo seznam bolnikov ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno porocanje prek Prijavnic je tako ukinjeno. Za zbolele v letu 2017, ki so prikazani v tem porocilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem klinicnem centru Maribor, Pediatricni kliniki ter Klinicnem oddelku za hematologijo Univerzitetnega klinicnega centra Ljubljana. Dopolnilni vir podatkov Registra raka so zdravniška porocila o vzroku smrti, ki nam jih pošilja Nacio- nalni inštitut za javno zdravje RS ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na mater- nicnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem crevesu in danki. Za izracun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno preko varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne analize Državne zdravstvene podatkovne zbirke: - Register umrlihUpravniregistri: - CRP- GURS Presejalni programi: - ZORA- Svit- DORA Javno- zdravstveni zavodi: - Pasivna ali aktivna prijava Bolnišnicni register: - OIL- Golnik Klinicne in populacijske raziskave REGISTERRAKA RS Podatki9prostorske razporeditve raka nam omogoca tocno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Ge- odetske uprave RS (GURS). Pri razporeditvi prebi- valcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi zacasnem, kot je upoštevano v pripravi števila prebivalcev po klasicni »statisticni« definiciji. Pri izracunavanju in interpretiranju vecine kazalni- kov bremena raka so poleg podatkov o bolnikih kljucni tudi nacionalni podatki o številu prebivalcev in o njihovi starostni strukturi. Za Slovenijo je tocno število in starostna struktura prebivalcev na voljo za popisna leta že ves cas registracije raka. Nacio- nalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izracunu kazalnikov predpostavili, da je bila med dvema popisnima le- toma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoce dobiti ažuren podatek o številu in staro- stni strukturi prebivalcev. V letnih porocilih uporab- ljamo podatek o prebivalcih na datum 1. julij po- sameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statisticnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupi- nah za celotno Slovenijo za leto 2017 so prikazani v tabeli. Obdelava podatkov Podatke, prispele v Register raka posebej usposobljene medicinske sestre v procesu registracije kodi- rajo v skladu z mednarodnimi in v registru dogovorjenimi pravili. Lokacija tumorja Za razvršcanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statisticne namene (MKB-10), pred tem pa smo uporabljali osmo. Od leta 1993 je obvezno prijavljanje sprememb maternicnega vratu, oznacenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, oznacene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepite- lijske spremembe maternicnega vratu uvršcene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Starostna skupina Age group Skupaj All Moški Males Ženske Females 0-4 104641 53807 50834 5-9 110822 57050 53772 10-14 94223 48408 45815 15-19 92875 48074 44801 20-24 101880 52496 49384 25-29 120713 62660 58053 30-34 139091 72723 66368 35-39 156318 82397 73921 40-44 153308 80000 73308 45-49 145866 75223 70643 50-54 155103 78618 76485 55-59 148609 74783 73826 60-64 147083 73577 73506 65-69 123777 59943 63834 70-74 87383 39379 48004 75-79 77709 32646 45063 80-84 57714 21012 36702 85+ 49046 13177 35869 Skupaj / Total 2066161 1025973 1040188 Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2017. Population of Slovenia by age and sex on July 1st 2017. 9prostorske razporeditve raka nam omogoca tocno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Ge- odetske uprave RS (GURS). Pri razporeditvi prebi- valcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni in ne tudi zacasnem, kot je upoštevano v pripravi števila prebivalcev po klasicni »statisticni« definiciji. Pri izracunavanju in interpretiranju vecine kazalni- kov bremena raka so poleg podatkov o bolnikih kljucni tudi nacionalni podatki o številu prebivalcev in o njihovi starostni strukturi. Za Slovenijo je tocno število in starostna struktura prebivalcev na voljo za popisna leta že ves cas registracije raka. Nacio- nalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izracunu kazalnikov predpostavili, da je bila med dvema popisnima le- toma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoce dobiti ažuren podatek o številu in staro- stni strukturi prebivalcev. V letnih porocilih uporab- ljamo podatek o prebivalcih na datum 1. julij po- sameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statisticnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupi- nah za celotno Slovenijo za leto 2017 so prikazani v tabeli. Obdelava podatkov Podatke, prispele v Register raka posebej usposobljene medicinske sestre v procesu registracije kodi- rajo v skladu z mednarodnimi in v registru dogovorjenimi pravili. Lokacija tumorja Za razvršcanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statisticne namene (MKB-10), pred tem pa smo uporabljali osmo. Od leta 1993 je obvezno prijavljanje sprememb maternicnega vratu, oznacenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, oznacene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepite- lijske spremembe maternicnega vratu uvršcene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03). Starostna skupina Age group Skupaj All Moški Males Ženske Females 0-4 104641 53807 50834 5-9 110822 57050 53772 10-14 94223 48408 45815 15-19 92875 48074 44801 20-24 101880 52496 49384 25-29 120713 62660 58053 30-34 139091 72723 66368 35-39 156318 82397 73921 40-44 153308 80000 73308 45-49 145866 75223 70643 50-54 155103 78618 76485 55-59 148609 74783 73826 60-64 147083 73577 73506 65-69 123777 59943 63834 70-74 87383 39379 48004 75-79 77709 32646 45063 80-84 57714 21012 36702 85+ 49046 13177 35869 Skupaj / Total 2066161 1025973 1040188 Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2017. Population of Slovenia by age and sex on July 1st 2017. Morfologija tumorja Pri uvršcanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne, in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvršcamo med posebne histološke vrste šele od leta 2001. V skladu z novimi pravili mejno malignih tumorjev jajcnikov ne uvršcamo vec v kategorijo C56, pac pa v D39.1. Po tretji reviziji so med maligne uvršcene kronicne mieloproliferativne bolezni in mielodisplasticni sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvršcamo v skupino C94. Z razvojem molekularne in genske tehnologije je mogoce natancneje opredeliti vrsto celicnih sprememb, ki nastanejo pri malignomih krvotvornega in limfaticnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se veca tudi število razlicnih vrst bolezni, njihovo razvršcanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila posebno klasifikacijo, ki opredeljuje malignome krvotvornega in limfaticnega tkiva glede na imunofenotip, genetske spremembe in klinicno sliko. Leta 2008 je bila ta klasifikacija posodobljena in v kliniki zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfaticnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo (3. izdaja, dopolnitev 2011). Stadij bolezni Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih porocilih pri solidnih tumorjih uporabljamo poenostavljeno razvršcanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, ce bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvršcen primer bolezni, pri katerem je tumor oznacen s T1 ali T2. Pri dojki, kožnem melanomu in šcitnici so v omejen stadij vkljuceni tudi tumorji T3; pri maternicnem vratu, maternicnem telesu in sarkomih, ter pri jajcniku, jajcevodu in trofoblastnih tumorjih v omejen stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete podrocne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer bolezni, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi podrocne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvršcamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). V bazi RRRS hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, ce je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo tudi po klasifikaciji FIGO, pri kožnem melanomu beležimo tudi velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor. Kakovost podatkov V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima indirektnima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških porocil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli. Incidenca raka glede na nacin postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2017. Cancer incidence according to basis of diagnosis, Slovenia 2017. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Mikroskopsko potrjeni primeri Microscopically confirmed cases Ugotovljeni z drugimi preiskavami Confirmed by other investigations Registrirani samo iz zdravniških porocil o vzroku smrti Registered from death certificates only Število Number % Število Number % Število Number % C00-C96 Vse lokacije All sites Moški in ženske / Males and females Moški / Males Ženske / Females 14987 7974 7013 14276 7597 6679 95,3 95,3 95,2 670 360 310 4,5 4,5 4,4 41 17 24 0,3 0,2 0,3 C00-C14 Usta in žrelo / Mouth and pharynx 350 349 99,7 1 0,3 0 0,0 C15 Požiralnik / Oesophagus 88 83 94,3 5 5,7 0 0,0 C16 Želodec / Stomach 425 413 97,2 10 2,4 2 0,5 C18 Debelo crevo / Colon 783 765 97,7 17 2,2 1 0,1 C19-C20 Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction 538 524 97,4 12 2,2 2 0,4 C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 262 150 57,3 110 42,0 2 0,8 C23-C24 Žolcnik in žolcevodi / Gallbladder and billiary tract 195 135 69,2 59 30,3 1 0,5 C25 Trebušna slinavka / Pancreas 410 270 65,9 136 33,2 4 1,0 C32 Grlo / Larynx 94 94 100,0 0 0,0 0 0,0 C33-C34 Sapnik, sapnici in pljuca / Trachea, bronchus and lung 1457 1359 93,3 92 6,3 6 0,4 C43 Maligni melanom kože / Malignant melanoma of skin 578 578 100,0 0 0,0 0 0,0 C44 Druge maligne neoplazme kože / Skin, other malignomas 3156 3147 99,7 9 0,3 0 0,0 C48-C49 Vezivno in mehko tkivo / Connective and soft tissue 71 71 100,0 0 0,0 0 0,0 C50 Dojka / Breast 1409 1398 99,2 5 0,4 6 0,4 C53 Maternicni vrat / Cervix uteri 86 85 98,8 1 1,2 0 0,0 C54 Maternicno telo / Corpus uteri 351 349 99,4 1 0,3 1 0,3 C56 Jajcnik / Ovary 157 147 93,6 10 6,4 0 0,0 C61 Prostata / Prostate 1595 1545 96,9 45 2,8 5 0,3 C62 Modo / Testis 125 125 100,0 0 0,0 0 0,0 C64-C65 Ledvica z ledvicnim mehom / Kidney with renal pelvis 403 362 89,8 40 9,9 1 0,2 C67 Secni mehur / Bladder 357 351 98,3 5 1,4 1 0,3 C70-C72 Centralni in avtonomni živcni sistem / Central and autonomic nervous system 201 174 86,6 27 13,4 0 0,0 C73 Šcitnica / Thyroid gland 211 211 100,0 0 0,0 0 0,0 C81 Hodgkinova limfom / Hodgkin’s lymphoma 57 57 100,0 0 0,0 0 0,0 C82-C85 Ne-Hodgkinovi limfomi / Non-Hodgkin’s lymphoma 390 390 100,0 0 0,0 0 0,0 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms 141 141 100,0 0 0,0 0 0,0 C91-C95 Levkemije / Leukaemias 329 329 100,0 0 0,0 0 0,0 Data12Data Data Sources Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databa- ses. The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via a special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registers collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals the Notification forms are filled in by the treating physicians or by the staff who they authorize. In accordance with the goals of the Natio- nal Cancer Control Program for 2017-2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting through Notification Forms will gradually be phased out. For patients diagnosed in 2017, data on whom are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana. Complementary sources of information for the Cancer Registry are death certificates that we get from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of precancerous and National Health Databases: - DeathRegistry Administrative registries: - CPR - SMARS Screening programmes: - ZORA- Svit - DORA Public Health Institutions: - Passsive or active registration Hospital- based registries: - IOL - Golnik Clinical and demographicresearch SLOVENIAN CANCERREGISTRY 12Data Data Sources Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databa- ses. The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via a special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registers collect data for the Notification form and then send it electronically to the Cancer Registry; in other hospitals the Notification forms are filled in by the treating physicians or by the staff who they authorize. In accordance with the goals of the Natio- nal Cancer Control Program for 2017-2021, in 2019 we began introducing data collection via so-called active registration, where hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting through Notification Forms will gradually be phased out. For patients diagnosed in 2017, data on whom are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana, the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana. Complementary sources of information for the Cancer Registry are death certificates that we get from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed cancers that are recorded in three national screening programs: ZORA for the detection of precancerous and National Health Databases: - DeathRegistry Administrative registries: - CPR - SMARS Screening programmes: - ZORA- Svit - DORA Public Health Institutions: - Passsive or active registration Hospital- based registries: - IOL - Golnik Clinical and demographicresearch SLOVENIAN CANCERREGISTRY early cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for the detection of precancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient’s vital status (whether the person is alive, dead or lost to follow-up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accurately defined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis, and not the temporary one, contrary to the standard “statistical” definition of the population used for calculating the number of inhabitants. In addition to patient data, national population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. The census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In Annual Reports the population data on July 1 of a particular year are used, which are obtained from the SI-STAT Data Portal of the Statistical Office of the Republic of Slovenia. In the table on page 9, numbers of inhabitants of Slovenia in 2017 by age and sex are presented. Data Processing In the Cancer Registry, specially trained nurses code the data retrieved from notifications of cancer in accordance with international and internal Registry guidelines for cancer registration. Tumour Location Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8th revision was used (ICD8). In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well. Tumour Morphology When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the third edition has been in use, including the 2011 updates. In this edition some changes were introduced in terms of morphology and behaviour coding and some new morphology codes were added for tumours that before 2001 were not coded separately. For example, gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to the new rules, ovarian tumours of borderline malignancy are currentlycoded as D39.1 (and not C56). According to the third edition, chronic myeloproliferative disorders and myelodysplastic syndromes as well as polycythaemia are classified as malignant, the former two being assigned to C96.7, while the polycythaemia is classified under the topography code C94 from year 2001 on. Development of molecular and genetic technologies enabled more detailed classification of the type of cellular changes, found in neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a greater number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2008 and replaced several other classifications of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology (third revision, 2011 update) follows this classification. Cancer Staging For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer T3 tumour is also included in localized stage. In uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours onlyT1 tumour is included in localized stage. In all of these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the distant stage (M1). Stage according to TNM or any other appropriate classification is also stored in the Cancer Registry database, if available. Additionally, FIGO classification is used for gynaecological tumours, size according to Clark’s level and Breslow’s thickness in skin melanoma, and Ann-Arbor System for malignant lymphomas. Data Quality The quality of information can be directly assessed by the following standard internationally harmonized parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in table on page 11. Rak v Sloveniji Povzetek Za dodatne podatke o bremenu raka v Sloveniji in svetu obišcite: www.slora.si. . Od rojenih leta 2017 bosta do svojega 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk. . Za rakom zboli letno okrog 15.000 Slovencev, skoraj 8.000 moških in vec kot 7.000 žensk, umre pa jih vec kot 6.000, približno 3.500 moških in 2.800 žensk; med nami živi že vec kot 100.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca). . Kljub temu, da se ogroženost z rakom zmerno veca, je najvecja pri starejših; od vseh rakavih bolnikov, zbolelih leta 2017, jih je bilo vec kot 60 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno vecjega deleža starejših pricakovati, da se bo število novih primerov raka še vecalo. . Najpogostejši raki pri nas (kože, prostate, debelega crevesa in danke, pljuc, pa tudi dojke) so leta 2017 predstavljali 60 % vseh ugotovljeni rakov. Povezani so z nezdravim življenjskim slogom, cezmernim soncenjem, nepravilno prehrano, kajenjem in cezmernim pitjem alkoholnih pijac; ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Presejalni programi za rake, ki jih priporoca Svet Evropske zveze (EZ) in smo jih uvedli tudi v Sloveniji, bodo z zgodnjim odkrivanjem zmanjšali umrljivost za rakom dojk, debelega crevesa in danke ter rakom maternicnega vratu; pri slednjih dveh bodo zmanjšali tudi incidenco. . Petletno cisto preživetje odraslih slovenskih bolnikov s katero koli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2013–2017, je bilo 57 %, bolnic pa 60 %. 0 20.000 40.000 60.000 80.000 100.000 120.000 7.974 7.013 6.3653.5702.79550.941 14.987 Incidenca Incidence Umrljivost Mortality 111.696 Prevalenca Prevalence 60.755 Moški in ženske / Males and females Moški / Males Ženske / Females Slika 1. Breme raka, Slovenija 2017. Figure 1. Cancer burden, Slovenia 2017. Osnovni podatki o raku v Sloveniji 2017 . Leta 2017 je v Sloveniji za rakom zbolelo 14.987 ljudi (7.974 moških in 7.013 žensk). . Starostno standardizirana incidencna stopnja (evropsko prebivalstvo) je bila 484,9/100.000; 563,9 pri moških in 430,3 pri ženskah. Od rojenih leta 2017 bosta do svojega 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk. . Leta 2017 je za rakom umrlo 6.365 Slovencev, 3.570 moških in 2.795 žensk. Med nami je živelo 111.696 ljudi (50.941moških in 60.755 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca). . Med posameznih slovenskih regijah ne opažamo bistvenih razlik v bremenu raka. Starost bolnikov . Ceprav se ogroženost z rakom zmerno veca, je najvecja v poznejših letih; od vseh rakavih bolnikov je leta 2017 kar 64 % moških in 60 % žensk zbolelo po dopolnjeni starosti 65 let. Manj kot odstotek vseh rakavih bolezni je ugotovljenih pri otrocih in mladostnikih (do 20. leta). . Ker se slovensko prebivalstvo stara, je samo zaradi cedalje vecjega deleža starejših pricakovati, da se bo število novih primerov raka še vecalo. Ocenjujemo, da je bilo leta 2020 že 15.800 novih bolnikov. 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85+ 150.000 100.000 50.000 0 0 500 1000 1500 2000 Število prebivalcev / Population Incidenca / Incidence Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2017. Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2017. Casovni trend . V splošnem se groba incidencna in umrljivostna stopnja raka vecata. . Groba incidencna stopnja se je v zadnjih dvajsetih letih skoraj podvojila, v zadnjem desetletju se veca za 2 % povprecno letno (1,9 % pri moških in 2,1 % pri ženskah). Groba umrljivostna stopnja se je pri moških v zadnjih 10-ih letih vecala povprecno za 1,0 % letno, pri ženskah pa za 0,8 %. . Vec kot polovica tega povecanja gre pripisati staranju prebivalstva, saj ima z daljšo življenjsko dobo tudi vec ljudi možnost docakati to bolezen. Starostno standardizirana, kumulativna incidencna stopnja kaže, da se tveganje raka veca pocasneje, pri moških se trend celo obraca navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (ce ne upoštevamo staranja) manjša, predvsem od sredine devetdesetih let, kar kaže na vecjo uspešnost zdravljenja. Leto / Year Incidenca moški Umrljivost moškiIncidenca ženske Umrljivost ženske Incidence males Mortality males Incidence females Mortality females Slika 3. Groba letna incidencna in umrljivostna stopnja vseh rakov po spolu spovprecno letno spremembo za zadnjih 10 let, Slovenija 1950-2017. Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex withaverage annual change in last 10 years, Slovenia 1950-2017. Leto / Year Incidenca moški Umrljivost moškiIncidenca ženske Umrljivost ženskeIncidence males Mortality males Incidence females Mortality females Slika 4. Kumulativna incidencna in umrljivostna stopnja vseh rakov po spolus povprecno letno spremembo v zadnjih 10 letih, Slovenija 1950-2017. Figure 4. Cumulative annual incidence and mortality rates for all cancer sites by sexwith average annual change in last 10 years, Slovenia 1950-2017. 20002005 2000200550 40 30 20 10 0 Kumulativna stopnja na 100.000Cumulative rate per 100,000 -0,3 % +1,2* % -2,0* % -0,4* % 1950 800 700 600 500 400 300 200 100 0 Groba stopnja na 100.000Crude rate per 100,000 +1,9* % +2,1* % +1,0* % +0,8* % 1950 1955 1955 1960 1960 1965 1965 1970 1970 1975 1975 1980 1980 1985 1985 1990 1990 1995 1995 2010 2010 2015 2015 2017 2017 Najpogostejši raki . Rak ni ena sama bolezen, temvec vec sto razlicnih. Te lahko vzniknejo v vseh tkivih in organih cloveškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi razlicne bolj ali manj znane nevarnostne dejavnike. . Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), prostate, raki debelega crevesa in danke, dojke in pljuc obsegajo 60 % vseh novih primerov rakavih bolezni. . Najpogostejši raki so povezani z nezdravim življenjskim slogom, cezmernim soncenjem, nepravilno prehrano, kajenjem in cezmernim pitjem alkoholnih pijac. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. . Pri moških je bil z 20 % vseh rakov na prvem mestu rak prostate, sledili so mu kožni rak (brez melanoma), pljucni rak in rak debelega crevesa in danke. Pri ženskah zavzemata nemelanomski kožni rak in rak dojke vsak po petino vseh rakov, sledijo pljucni rak ter debelega crevesa in danke. . Najpogostejši raki so v raznih življenjskih obdobjih razlicni. Pri otrocih in mladostnikih do 20. so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živcnega sistema. Mlajši odrasli moški zbolevajo najvec za rakom mod, pri ženskah v tej straosti pa je na prvem mestu že rak dojke. Moški in ženske Males and females Koža, razen melanoma Skin, non-melanoma Prostata Prostate Pljuca* Lung* Dojka Breast Debelo crevno in danka* Colorectum* Koža, melanoma Skin, melanoma Glava in vrat* Head and neck* Želodec Stomach Trebušna slinavka Pancreas Ledvica z ledvicnim mehom* Kidney with renal pelvis* Ostalo Other 21,1 10,6 9,7 9,4 8,8 3,9 3,1 2,8 2,7 2,7 25,2 250 5 10 15 20 30 % *Pojasnilo / ExplanationGlava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ledvica z ledvicnim mehom / Kidney with renal pelvis (C64-C65) Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2017. Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2017. Dojka Breast Prostata Koža, razen melanoma Ostalo Glava in vrat* Head and neck*4,6 Pljuca* Lung* 11,1 9,9 3,5 3,2 20,0 19,4 3,8 18,8 2,3 8,1 19,9 7,6 5,0 2,8 22,9 4,0 21,8 Pljuca* Lung* Šcitnica Thyroid gland 2,53,0Trebušna slinavka Pancreas Trebušna slinavka Pancreas 3,1 2,5Želodec Stomach Želodec Stomach Debelo crevo in danka* Colorectum* Debelo crevo in danka* Colorectum* Maternicno telo Corpus uteri Ledvica z ledvicnim mehom* Kidney with renal pelvis* Mehur Bladder Ne-Hodgkinovi limfomiNon-Hodkgin’s lymphoma Koža, melanom Skin, melanoma Koža, melanom Skin, melanoma ŽenskeFemalesMoškiMales Prostate Koža, razen melanoma Skin, non-melanoma Skin, non-melanoma Ostalo Other Other 30 %2520 1510 5 0 5 1015202530 % *Pojasnilo / Explanation: Glava in vrat / Head and neck (C00-C14, C30-C32) Debelo crevo in danka / Colorectum (C18-C20) Sapnik, sapnici in pljuca / Trachea, bronchus and lung (C33-C34) Ledvica z ledvicnim mehom / Kidney with renal pelvis (C64-C65) Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2017. Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2017. Starost 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 28,3 Ostalo 25,2 Ostalo 31,5 Ostalo 35,7 Ostalo 34,0 Ženske Females Kosti Hodgkinov limfom Šcitnica Centralni in avtonomni živcni sistem Levkemije Debelo crevo in danka Maternicni vrat Šcitnica Koža, melanom Koža, razen melanoma Vezivno in mehko tkivo Dojka Koža, razen melanoma Dojka 6,9 7,5 Koža, razen melanoma Dojka Debelo crevo in danka Pljuca 8,1 12,3 27,7 Koža, razen melanoma Dojka Debelo crevo in danka Debelo crevo in danka 10,5 Pljuca Pljuca5,9 Maternicno telo Maternicno telo 6,6 5,2 Maternicno telo Koža, melanom Koža, melanom 3,5 3,9 Trebušna slinavka 9,3 10,4 16,8 20,8 4,1 5,4 7,3 9,0 16,2 32,8 9,8 17,8 22,7 4,1 3,9 7,4 8,5 20,1 21,0 Povprecna letna incidenca 35 824 3439 2409 6706 Age 0–19 20–49 50–74 75+ Vse starosti / All Ostalo 27,4 Ostalo 34,9 Ostalo 27,7 Ostalo 27,8 Ostalo 31,2 Moški Males Modo Ne-Hodgkinovi limfomi Hodgkinov limfom Centralni in avtonomni živcni sistem Levkemije Ne-Hodgkinovi limfomi Glava in vrat Debelo crevo in danka Koža, melanom Koža, razen melanoma Kosti Modo Koža, razen melanoma Prostata 7,8 8,2 Koža, razen melanoma Prostata Prostata 17,7 23,8 Koža, razen melanoma 18,0 Debelo crevo in danka Pljuca10,4 Debelo crevo in danka Debelo crevo in danka 11,3Pljuca 13,4 Pljuca Glava in vrat 4,7 Želodec Glava in vrat Koža, melanom 5,8 4,4Ledvica z ledvic. mehom 3,5 Secni mehur 9,1 11 14,1 22,4 4,4 6,5 8,0 10,9 17,4 17,9 15,3 23,9 4,8 10,2 3,7 10,4 11,7 20,3 Average annual incidence 44 558 4894 2430 7926 *Pojasnilo / Explanation: Debelo crevo in danka / Colorectum (C18-C20) Dojka / Breast (C50)Želodec / Stomach (C16) Trebušna slinavka / Pancreas (C25) Maternicni vrat / Cervix uteri (C53) Prostata / Prostate (C61) Pljuca / Lung (C33-C34) Maternicno telo / Corpus uteri (C54)Modo / Testis (C62) Kosti / Bone (C40-C41)Centralni in avtonomni živcni sistem / Central and Ledvica z ledvicnim mehom / Kidney withKoža, melanom / Skin, melanoma (C43) autonomic nervous system (C70-C72) renal pelvis (C64-C65) Koža, razen melanoma / Skin, non-melanoma (C44) Šcitnica / Thyroid gland (C73) Secni mehur / Bladder (C67) Vezivno in mehko tkivo / Connective and soft tissue (C48-C49) Hodgkinov limfom / Hodgkin’s disease (C81) Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin’s Glava in vrat / Head and neck (C00-C14, C30-C32) Levkemije / Leukaemias (C91-C95) lymphoma (NHL) (C82-C85) Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2013-2017. Figure 6: Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2013-2017. Trend najpogostejših rakov . Med pogostejšimi rakavimi boleznimi se je pri moških incidencna stopnja pljucnega raka vecala vse do zacetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 90/100.000. . Strmo pa pljucnega raka prehitevata rak prostate (povecanje za povprecno 2,0 % na leto) in kožni nemelanomski rak (povecanje za povprecno 5,3 % na leto). Izjemno povecanje incidence raka prostate v prejšnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pac pa predvsem vse širše rabe testa za dolocanje za prostato specificnega antigena (PSA) pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugace ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate vseeno že dosegli. . Tudi casovne spremembe v pojavljanju raka debelega crevesa in danke je potrebno ocenjevati z upoštevanjem sprememb v diagnostiki – leta 2009 smo namrec v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem crevesu in danki (SVIT). Incidenca raka debelega crevesa in danke se je pri moških med leti 2008 in 2010 povecevala za 8,2 % letno , od leta 2010 do 2017 pa pada za 3,7 % letno. Povprecne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7. . Med pogostejšimi rakavimi boleznimi so se pri ženskah vecale incidencne stopnje raka dojk (za 2,0 % povprecno letno), kože, razen melanoma (povecanje za 4,3 % povprecno letno), pljucnega raka (za 5,9 % povprecno letno) in raka maternicnega telesa (za 2,8 % povprecno letno). . Incidencna stopnja raka maternicnega vratu od uvedbe Državnega presejalnega programa za odkrivanje predrakavih in zgodnjih rakavih sprememb na maternicnem vratu (ZORA) strmo pada (za povprecno 3,5 % na leto v zadnjih desetih letih). . Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa SVIT leta 2009 spreminja casovni trend pojavljanja raka debelega crevesa in danke – od leta 2008 pada incidenca raka debelega crevesa in danke za povprecno 2,3 % na leto. 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +2,0* % -2,0* % -0,7 % -1,3 % +5,3* % +0,8 % +2,6* % +3,9* % MoškiMales 195019551960196519701975198019851990199520002005201020152017 Pljuca / Lung (C33–C43) Prostata / Prostate (C61) Leto / Year Koža, razen melanoma / Skin, non-melanoma (C44) Glava in vrat / Head and neck (C00–C14, C30–C32) Debelo crevo in danka / Colorectum (C18–C20) Želodec / Stomach (C16) Mehur / Bladder (C67) Koža, melanoma / Skin, melanoma (C43) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7a. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2017. Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years inmales, Slovenia 1950-2017. Dojka / Breast (C50) Koža, razen melanoma / Skin, non-melanoma (C44) Leto / Year Debelo crevo in danka / Colorectum (C18–C20) Pljuca / Lung (C43) Maternicno telo / Corpus uteri (C54) Koža, melanoma / Skin, melanoma (C43) Maternicni vrat / Cervix uteri (C53) Želodec / Stomach (C16) * Povprecna letna sprememba je statisticno znacilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level Slika 7b. Groba letna incidencna stopnja izbranih rakov s povprecno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2017. Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years infemales, Slovenia 1950-2017. Redki raki . Poseben izziv državam so redke rakave bolezni (opredeljene kot tiste, ki jih je letno manj kot 6novih primerov na 100.000 prebivalcev). . Skupaj so redki raki v Sloveniji predstavljali približno petino od vseh novo ugotovljenih primerovraka – letno je za njimi zbolelo okrog 3.000 bolnikov. . Za redke rake je znacilno, da se v primerjavi s pogostejšimi veckrat pojavljajo pri otrocih in mladostnikih. . Kot pri vseh redkih boleznih so tudi pri redkih rakih težave podobne: pozno in težko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenjeni dostopno. Da bi uspešno obvladovali redke rake je pomembno, da njihovo breme natancnospremljamo, ter da vse države sprejmejo smernice in dolocijo referencne centre za diagnostiko inzdravljenje teh bolnikov. Slika 8: Odstotni delež redkih, pogostih in nerazvršcenih rakovpo starostnih skupinah, Slovenija2004-2013. Figure 8: Percentage distribution of rare, common and unclassifiedcancers by age group, Slovenia2004-2013. 100 90 80 70 60 50 40 30 20 10 0 Nerazvršcen / UnclassifiedPogosti / CommonRedki / Rare % 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000200520102015 2017 160 140 120 100 80 60 40 20 0 Groba stopnja na 100.000Crude rate per 100,000 +2,0* % -2,3* % +2,8 % -1,4 % +4,3* % +5,9* % -3,5* % +1,0* % ŽenskeFemales Age / Starost 0–45–9 10–1415–19 20–2425–29 30–3435–39 40–4445–49 50–54 55–5960–64 65–6970–74 75–7980+ Vsi Preživetje . Petletno cisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2013–2017, je bilo že 56,7 %, pri ženskah pa je preseglo 60 %. . Vec kot 80 % je bilo cisto 5-letno preživetje pri moških z rakom mod, šcitnice, Hodgkinovo boleznijo, rakom prostate in kožnim melanomom. Pri ženskah pa pri bolnicah z rakom šcitnice, kožnim melanomom, Hodgkinovo boleznijo, rakom dojk in rakom maternicnega telesa. . V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov zbolelih med leti 1997 in 2016. Rezultati analize so na voljo v publikaciji Zadnik V, Žagar T, Lokar K, Tomšic S, Duratovic Konjevic A, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji, ki je dostopna v pdf obliki tudi na www.onko-i.si/rrs. Glavni zakljucki so: 1. Preživetje slovenskih bolnikov z rakom se s casom povecuje. V zadnjih 20. letih (1997-2001 in 2012-2016) se je petletno cisto preživetje povecalo za 11 odstotnih tock. Obcutno vecja je rast pri moških kjer se je petletno cisto preživetje povecalo za 17 odstotnih tock (iz 38 % na 55 %). Pri ženskah je petletno cisto preživetje zraslo za 6 odstotnih tock (iz 54 % na 60 %). 2. Kljucna za preživetje bolnikov z rakom sta še vedno starost in stadij ob diagnozi. Petletno cisto preživetje je najmanjše pri starejših od 75 let, se je pa tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih tock. Petletno cisto preživetje bolnikov z omejenim stadijem se je v 20. letih povišalo za 10 odstotnih tock; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje. 3. Pri obeh spolih so se v zadnjih 20. letih znacilno povecala preživetja pri treh pogostih rakih: raku na debelem crevesu in danki (za 14 odstotnih tock iz 48 % na 62 %), kožnem melanomu (za 12 odstotnih tock iz 79 % na 91 %) ter pri pljucnem raku (za 8 odstotnih tock iz 10 % na 18 %). Rezultat odraža zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju. 4. Obcuten je tudi napredek pri obeh najpogostejših rakih, raku dojke pri ženskah in raku prostate pri moških: petletno cisto preživetje bolnic z rakom dojke se je v zadnjih 20. letih povecalo za 10 odstotnih tock, petletno cisto preživetje bolnikov z rakom prostate pa celo za vec kot 20 odstotnih tock. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekriticno uporabljali testiranje PSA s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinicno nemi ter tako, s predhodno diagnozo, umetno podaljšali preživetja. 5. V skupino rakov, kjer napredka s casom ni opaziti ter pri katerih preživetja še vedno ostajajo slaba, pa sodijo rak trebušne slinavke, rak požiralnika, raki jeter, žolcnika in žolcevodov ter možganski tumorji. 6. V raziskavi CONCORD-3 smo primerjali petletna cista preživetja odraslih bolnikov s petnajstimi razlicnimi vrstami raka zbolelimi med leti 2010 in 2014 v 26. evropskih državah. Preživetja slovenskih bolnikov z rakom so v vecini primerov pod evropskim povprecjem, kar nam daje dobro osnovo za nadaljnje izboljšave. 7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zbolevajo predvsem za levkemijami, tumorji osrednjega živcevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997-2001 in 2012-2016) se je petletno preživetje otrok in mladostnikov zbolelih za rakom povecalo za 7 odstotnih tock (iz 79 % na 86 %). Modo Testis Prostata Prostate Koža, melanom Skin, melanoma Šcitnica Thyroid gland Hodgkinov limfom Hodgkin’s lymphoma Limfaticna levkemija Lymphocytic leukaemia Kosti Bone Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Ledvica z ledvicnim mejom Kidney with renal pelvis Rektum in rektosigmoizna zveza Rectum and rectosigmoid junction Debelo crevo Colon Grlo Larynx Vezivno in mehko tkivo Connective and soft tissue Secni mehur Bladder Usta Mouth Levkemije, drugo Leukaemias, other Želodec Stomach Žrelo Pharynx Sapni, sapnici in pljuca Trachea, bronchus and lung Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts Požiralnik Oseophagus Trebušna slinavka Pancreas Vsi raki, razen kožnega All cancer sites but skin Moški Males C43 C61 C33–C34 C40–C41 C18 C48–C49 C32 C16 C25 C64–C65 C00–C96 brez C44 C62 C73 C81 C91 C82–C85 C19–C20 C67 C00–C09 C92–C95 C10–C14 C22 C15 20 400 60 80 100 Preživetje je vec kot 50 % (62,3 % vseh ugotovljenihrakov v 2013–2017) Preživetje je 10–50 % (25,0 % vseh ugotovljenih rakov v 2013–2017) Preživetje je manj kot 10 % (3,0 % vseh ugotovljenih rakov v 2013–2017) 97,3 98,1 93,3 89,7 91,6 83,5 90,8 91,4 83,5 89,5 71,7 61,2 67,8 57,3 65,7 66,5 65,7 67,4 64,3 61,0 61,5 62,4 60,3 68,0 56,7 57,3 53,9 57,2 52,8 52,3 32,2 27,7 30,3 26,4 29,2 29,4 16,0 12,8 10,7 8,3 10,0 7,8 6,0 4,6 56,7 54,4 2013–2017 2008–2012 10 30507090% Slika 9a. Petletno cisto preživetje (s 95 % intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2013–2017 in 2008-2012. Figure 9a. Five-year net survival (with 95% confidence interval) for malesdiagnosed with selected cancers in periods 2013–2017 and 2008–2012. Šcitnica Thyroid gland Koža, melanom Skin, melanoma Hodgkinov limfom Hodgkin’s lymphoma Dojka Breast Maternicno telo Corpus uteri Usta Mouth Maternicni vrat Cervix uteri Ledvica z ledvicnim mejom Kidney with renal pelvis Limfaticna levkemija Lymphocytic leukaemia Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma Debelo crevo Colon Rektum in rektosigmoizna zveza Rectum and rectosigmoid junction Kosti Bone Vezivno in mehko tkivo Connective and soft tissue Secni mehur Bladder Žrelo Pharynx Jajcnik Ovary Levkemije, drugo Leukaemias, other Želodec Stomach Sapni, sapnici in pljuca Trachea, bronchus and lung Požiralnik Oseophagus Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts Trebušna slinavka Pancreas Vsi raki, razen kožnega All cancer sites but skin Ženske Females C81 C43 C33–C34 C53 C18 C48–C49 C19–C20 C92–C95 C25 C91 C00–C96 brez C44 C73 C50 C54 C00–C09 C64–C65 C82–C85 C67 C10-C14 C56 C16 C15 C22 More than 50 % survival (63,3 % of all cancers diagnosedin 2013–2017) 10–50 % survival (20,5 % of all cancers diagnosed in 2013–2017) Less than 10 % survival (3,6 % of all cancers diagnosed in 2013–2017) C40–C41 95,8 96,8 60,4 58,8 91,4 89,4 88,4 85,3 88,0 85,6 80,3 80,4 71,1 64,8 67,8 69,3 67,3 63,1 63,6 60,9 62,1 66,8 62,1 61,0 59,2 59,1 53,5 68,2 53,0 43,6 49,1 38,7 41,8 42,0 40,0 43,2 39,3 36,0 30,5 27,0 23,4 18,2 17,2 10,4 10,7 5,1 6,9 4,1 0 10 20 30 40 50 60 70 80 90100% 2013–2017 2008–2012 Slika 9b. Petletno cisto preživetje (s 95 % intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2013–2017 in 2008-2012. Figure 9b. Five-year net survival (with 95% confidence interval) for femalesdiagnosed with selected cancers in periods 2013–2017 and 2008–2012. Primerjava z Evropo . Kot je ocenjeno v okviru Evropskega informacijskega sistema za raka (https://ecis.jrc.ec.europa. eu/), je bila Slovenija leta 2020 po incidencni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (616/100.000) na osmem mestu med 27 evropskimi državami. Višjo incidenco so imele Irska, Danska, Nizozemska, Belgija, Ciper, Madžarska in Francija. . Po umrljivostni stopnji smo na sedmem mestu, pred nami so Slovaška, Poljska, Ciper, Madžarska, Hrvaška in Danska. 458,0–510,1 510,1–562,1 562,1–614,2 614,2–666,2 666,2–718,3 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 EU-27, vse lokacije brez nemelanomskega kožnega, vse starosti, oba spola 2020EU-27, all sites but non-melanoma skin, all ages, both sexes, 2020 Ocena incidence po državahEstimated incidence by country Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidencna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020. Figure 10a. Estimated age standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2020. 213,9–241,5 241,5–268,0 269,0–296,6 296,6–324,1 324,1–351,7 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by country EU-27, vse lokacije brez nemelanomskega kožnega, vse starosti, oba spola 2020EU-27, all sites but non-melanoma skin, all ages, both sexes, 2020 213,9–241,5 241,5–268,0 269,0–296,6 296,6–324,1 324,1–351,7 Starostno standardizirana stopnja na 100.000Age standardized rate (European new) per 100.000 Ocena umrljivosti po državahEstimated mortality by country EU-27, vse lokacije brez nemelanomskega kožnega, vse starosti, oba spola 2020EU-27, all sites but non-melanoma skin, all ages, both sexes, 2020 Vir: ECIS - Evropski informacijski sistem za rakahttps://ecis.jcr.ec.europa.eu Source: ECIS - European Cancer Information System Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2020. Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2020. Cancer in Slovenia28Cancer in Slovenia For additional information on the burden of cancer in Slovenia and the world, visit: www.slora.si. Figures are available on pages 15–27. Basic figures on cancer in Slovenia 2017 .In 2017, 14,987 people (7,974 men and 7,013 women) were diagnosed with cancer in Slovenia. .The age-standardized incidence rate (European standard population) was 484.9/100,000; 563.9 in men and 430.3 in women. Among those born in 2017, one in two men and one in three wom- en are expected to develop cancer by the age of 75. .In 2017, 6,365 Slovenians died of cancer, 3,570 men and 2,795 women. There were 111,696 people alive in Slovenia (50,941 men and 60,755 women) who had at some point during their lifetime been diagnosed with cancer (prevalence). .There are no significant differences in the burden of cancer between regions of Slovenia. Age of patients .Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2017, as many as 64% men and 60% women were diagnosed with cancer after the age of 65. Less than one percent of all cancers were diagnosed in children and adolescents (up to 20 years of age). .Among those born in 2017, one in two men and one in three women are expected to de- velop cancer by the age of 75. .Every year, around 15,000 Slovenians (almost 8,000 men and more than 7,000 women) are diagnosed with cancer, and more than 6,000 (about 3,500 men and 2,800 women) die of cancer. Currently, there are already over 100,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence). .The risk of developing cancer increases gradually with age and is highest among the older population; of all cancer patients diagnosed in 2017, more than 60% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of older people. .In 2017, the most frequent cancers in Slovenia (skin, prostate, colorectal, lung, and breast) accounted for 60% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consump- tion – primary prevention measures should be in place with the aim to reduce their burden. .Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia are expected to lower mortality from breast, col- orectal and cervical cancer through early detection; for colorectal and cervical cancer, a reduction in cancer incidence is also expected. .The five-year net survival of adult Slovenian patients with any type of cancer (excludingnon-melanoma skin cancer) who were diagnosed in the 2013–2017 period was 57% in menand 60% in women. Summary28Cancer in Slovenia For additional information on the burden of cancer in Slovenia and the world, visit: www.slora.si. Figures are available on pages 15–27. Basic figures on cancer in Slovenia 2017 .In 2017, 14,987 people (7,974 men and 7,013 women) were diagnosed with cancer in Slovenia. .The age-standardized incidence rate (European standard population) was 484.9/100,000; 563.9 in men and 430.3 in women. Among those born in 2017, one in two men and one in three wom- en are expected to develop cancer by the age of 75. .In 2017, 6,365 Slovenians died of cancer, 3,570 men and 2,795 women. There were 111,696 people alive in Slovenia (50,941 men and 60,755 women) who had at some point during their lifetime been diagnosed with cancer (prevalence). .There are no significant differences in the burden of cancer between regions of Slovenia. Age of patients .Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2017, as many as 64% men and 60% women were diagnosed with cancer after the age of 65. Less than one percent of all cancers were diagnosed in children and adolescents (up to 20 years of age). .Among those born in 2017, one in two men and one in three women are expected to de- velop cancer by the age of 75. .Every year, around 15,000 Slovenians (almost 8,000 men and more than 7,000 women) are diagnosed with cancer, and more than 6,000 (about 3,500 men and 2,800 women) die of cancer. Currently, there are already over 100,000 people living in Slovenia, who have at some point during their lifetime been diagnosed with cancer (prevalence). .The risk of developing cancer increases gradually with age and is highest among the older population; of all cancer patients diagnosed in 2017, more than 60% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of older people. .In 2017, the most frequent cancers in Slovenia (skin, prostate, colorectal, lung, and breast) accounted for 60% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consump- tion – primary prevention measures should be in place with the aim to reduce their burden. .Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia are expected to lower mortality from breast, col- orectal and cervical cancer through early detection; for colorectal and cervical cancer, a reduction in cancer incidence is also expected. .The five-year net survival of adult Slovenian patients with any type of cancer (excludingnon-melanoma skin cancer) who were diagnosed in the 2013–2017 period was 57% in menand 60% in women. Summary . As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of older people. We estimate that in 2020, there were as many as 15,800 newly diagnosed cancer patients. Time trends . In general, the crude incidence and mortality rates of cancer are increasing. . The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 2% per year over the last decade (by 1.9% in men and 2.1% in women). The crude mortality rate has increased on average by 1.0% per year in men over the last 10 years, and by 0.8% in women. . More than half of this increase can be attributed to an ageing population, as longer life expectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend even reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment. Most frequent cancers . Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment, and outcome, and are also associated with different, more or less established risk factors. . The five most frequent cancers in Slovenia – skin (excluding melanoma), prostate, colorectal, breast and lung – account for 60% of all new cancer cases. . The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden. . In men, prostate cancer was most frequent, accounting for 20% of all cancers, followed by skin cancer (excluding melanoma), lung cancer, and colorectal cancer. In women, non-melanoma skin cancer and breast cancer each account for one-fifth of all cancers, followed by lung cancer and colorectal cancer. . The most frequent cancers differ according to age. In children and adolescents aged up to 20 years, leukaemias are most frequent, followed by tumours of the central and autonomic nervous system. Young adult men are most often diagnosed with testicular cancer, while in young women, breast cancer is already ranked first. Time trends for most frequent cancers . Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 1990s, when it stabilized at around 90/100,000. . Lung cancer is outranked by the steep rising rates of prostate cancer (an increase of 2.0% per year on average) and non-melanoma skin cancer (an increase of 5.3% on average per year). The dramatic increase in the incidence of prostate cancer over the past decade is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years indicate that we have already reached the peak incidence of prostate cancer. . Time trends in the incidence of colorectal cancer must also be interpreted by taking into account changes in diagnostics – in 2009 Slovenia introduced the national screening and early detection programme for colorectal cancer (Svit). The incidence of colorectal cancer in men increased by 8.2% per year between 2008 and 2010, and decreased by 3.7% per year from 2010 to 2017. Average annual percentage changes are shown next to the incidence curves in Figure 7. . Among the more frequent cancers in women, incidence rates have been increasing for breast cancer (by 2.0% on average per year), skin, excluding melanoma (by 4.3% on average per year), lung cancer (by 5.9% on average per year) and uterine cancer (by 2.8% on average per year). . The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 3.5% per year in the last ten years). . Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – since 2008 the incidence of colorectal cancer has been declining by an average of 2.3% per year. Rare cancers . A particular challenge for countries are rare cancers (defined as those with less than six new cases per 100,000 per year). . In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year. . As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents. . Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for the diagnostics and treatment of such patients. Survival . The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2013 and 2017 was 56.7%, while in women it was over 60%. . The five-year net survival was over 80% in men with testicular cancer, thyroid cancer, Hodgkin’s disease, prostate cancer, and skin melanoma, and in women with thyroid cancer, skin melanoma, Hodgkin's disease, breast cancer and uterine cancer. . In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication Zadnik V, Žagar T, Lokar K, Tomšic S, Duratovic Konjevic A, Zakotnik B. Survival of cancer patients, diagnosed in 1997– 2016 in Slovenia, which is also available in pdf format at www.onko-i.si/rrs. Main conclusions are on the next page. 1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%). 2. Age and stage at diagnosis are still key when it comes to survival of cancer patients. Five- year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. The five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; the survival of patients with distant disease has not improved. 3. In both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), melanoma of skin (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). The improvement is due to earlier diagnosis and advances in systemic treatment. 4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased by 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased by over 20 percentage points. The improvement in prostate cancer survival is probably not real since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease. 5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers, as well as brain tumours. 6. In the CONCORD-3 study five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases, survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements. 7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemia, central nervous system tumours and lymphomas, and have a better five- year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five- year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%). Comparisons with Europe . According to the estimates of the European Cancer Information System (https://ecis.jrc.ec.europa. eu/), in 2020 Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (616/100,000). Ireland, Denmark, the Netherlands, Belgium, Cyprus, Hungary and France had a higher incidence. . We are in seventh place in terms of mortality, led by Slovakia, Poland, Cyprus, Hungary, Croatia and Denmark. Incidenca Incidence Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2008-2017 in 2020. Table 1: Observed and estimated cancer incidence by sex, Slovenia 2008-2017 and 2020. Šifra Primarna Spol Povprecne letne opazovane vrednosti 2008-2012 Povprecne letne opazovane vrednosti 2013-2017 Ocena za 2020 MKB lokacija Število Incidencna stopnja na 100.000 Število Incidencna stopnja na 100.000 Število s 95 % napovednim intervalom Incidencna stopnja na 100.000 s 95 % napovednim intervalom ICD Primary Sex Average annual observed values 2008-2012 Average annual observed values 2013-2017 Estimation for 2020 code site Number Incidence rate per 100,000 Number Incidence rate per 100,000 Number with 95% prediction interval Incidence rate per 100,000 with 95% prediction interval C00- C96 Vse lokacije All sites M+Ž M Ž 13157 7162 5995 643,5 708 580,2 14632 7926 6706 709,3 775 644,7 8767 8518-9017 7484 7249-7719 16251 15909-16594 834 810-858 716 694-739 775 759-792 C00 Usta in žrelo M 276 27,3 273 26,7 265 223-308 25 21-29 -C14 Mouth and pharynx Ž 71 6,9 81 7,8 82 63-101 8 6-10 C15 Požiralnik Oesophagus M Ž 68 17 6,7 1,6 70 17 6,9 1,6 69 48-91 18 7-30 7 5-9 2 1-3 C16 Želodec Stomach M Ž 294 185 29,1 17,9 284 172 27,7 16,6 267 225-309 160 127-192 25 21-29 15 12-18 C18 Debelo crevo Colon M Ž 531 400 52,4 38,7 470 363 46 34,9 462 401-524 356 306-407 44 38-50 34 29-39 C19 Rektum in rektosigmoidna zveza M 415 41 355 34,7 315 270-361 30 26-34 -C20 Rectum and rectosigmoid junction Ž 247 23,9 204 19,6 171 138-203 16 13-19 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 124 45 12,3 4,4 160 61 15,7 5,9 208 168-248 77 55-100 20 16-24 7 5-10 C23 Žolcnik in žolcevodi M 69 6,9 86 8,4 103 75-132 10 7-13 -C24 Gallbladder and billiary tract Ž 102 9,9 107 10,3 108 81-135 10 8-13 C25 Trebušna slinavka Pancreas M Ž 169 181 16,7 17,5 199 191 19,4 18,4 224 183-264 202 164-239 21 17-25 19 16-23 C32 Grlo Larynx M Ž 92 11 9,1 1,1 87 12 8,5 1,1 84 60-108 11 0-21 8 6-10 1 0-2 C33 Sapnik, sapnici in pljuca M 868 85,9 927 90,6 946 865-1027 90 82-98 -C34 Trachea, bronchus and lung Ž 370 35,8 495 47,6 660 579-741 63 55-71 C43 Maligni melanom kože Malignant melanoma of skin M Ž 239 249 23,7 24,1 294 260 28,8 25 355 306-404 276 232-320 34 29-38 26 22-31 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 1086 1120 107,3 108,4 1426 1411 139,5 135,6 1794 1683-1905 1738 1621-1855 171 160-181 166 155-178 C48 Vezivno in mehko tkivo M 28 2,8 31 3 31 16-46 3 2-4 -C49 Connective and soft tissue Ž 38 3,7 43 4,2 49 30-68 5 3-6 C50 Dojka Breast M Ž 12 1218 1,2 117,9 12 1345 1,2 129,3 16 4-28 1474 1374-1575 1 0-3 141 131-151 C53 Maternicni vrat Cervix uteri M Ž - 132 - 12,8 - 113 - 10,9 - - 97 74-120 - - 9 7-12 C54 Maternicno telo Corpus uteri M Ž - 305 - 29,5 - 347 - 33,3 - - 395 343-447 - - 38 33-43 C56 JajcnikOvary M Ž - 165 - 16 - 157 - 15,1 - - 137 107-167 - - 13 10-16 C61 Prostata Prostate M Ž 1469 - 145,2 - 1613 - 157,7 - 1775 1662-1888 - - 169 158-180 - - C62 Modo Testis M Ž 104 - 10,2 - 117 - 11,4 - 137 105-169 - - 13 10-16 - - C64 Ledvica z ledvicnim mehom M 236 23,3 259 25,3 280 236-325 27 22-31 -C65 Kidney with renal pelvis Ž 118 11,5 138 13,2 143 111-175 14 11-17 C67 Secni mehur Bladder M Ž 219 80 21,7 7,7 255 97 25 9,3 283 238-329 114 85-143 27 23-31 11 8-14 C70 Centralni in avtonomni živcni sistem M 78 7,7 104 10,2 122 94-151 12 9-14 -C72 Central and autonomic nervous system Ž 64 6,2 74 7,1 82 59-106 8 6-10 C73 Šcitnica Thyroid gland M Ž 39 118 3,9 11,4 44 149 4,3 14,3 51 32-71 170 137-203 5 3-7 16 13-19 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 23 25 2,3 2,4 28 25 2,7 2,4 32 17-48 25 12-38 3 2-5 2 1-4 C82 Ne-Hodgkinovi limfomi M 162 16 215 21 273 224-323 26 21-31 -C85 Non-Hodgkin’s lymphoma Ž 161 15,6 202 19,5 249 205-292 24 20-28 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 69 63 6,8 6,1 73 61 7,2 5,9 82 58-106 58 38-78 8 5-10 6 4-7 C91 Levkemije M 160 15,9 182 17,8 201 172-230 19 16-22 -C95 Leukaemias Ž 124 12 137 13,2 148 116-180 14 11-17 Tabela 2: Incidenca, groba incidencna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidencne stopnje raka po spolu, Slovenija 2017. Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2017. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Število Number Groba incidencna stopnja na 100.000 Crude incidence rate per 100,000 SSS* - svetovni standard ASR* - World standard SSS* - evropski standard ASR* - European standard SSS* - slovenski standard ASR* - Slovenian standard C00-C96 Vse lokacije All sites M+Ž M Ž 14987 7974 7013 725,4 777,2 674,2 340,9 387,6 307,8 484,9 563,9 430,3 575,6 681,9 502,2 C00-C14 Usta in žrelo Mouth and pharynx M Ž 265 85 25,8 8,2 13,9 4,0 19,4 5,4 22,0 6,1 C15 Požiralnik Oesophagus M Ž 66 22 6,4 2,1 3,3 0,7 4,7 1,1 5,4 1,5 C16 Želodec Stomach M Ž 251 174 24,5 16,7 10,9 5,9 17,0 8,9 21,1 10,9 C18 Debelo crevo Colon M Ž 453 330 44,2 31,7 20,4 12,6 31,1 18,5 38,7 22,4 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 337 201 32,8 19,3 16,0 7,8 23,7 11,3 28,3 13,6 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 189 73 18,4 7,0 8,9 2,7 13,1 4,1 16,0 4,9 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 85 110 8,3 10,6 3,7 3,4 5,7 5,4 7,4 6,7 C25 Trebušna slinavka Pancreas M Ž 203 207 19,8 19,9 9,2 6,9 14,1 10,5 17,5 12,8 C32 Grlo Larynx M Ž 87 7 8,5 0,7 4,3 0,4 6,1 0,5 7,2 0,6 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 887 570 86,5 54,8 41,8 24,4 61,8 35,0 74,2 40,7 C43 Maligni melanom kože Malignant melanoma of skin M Ž 300 278 29,2 26,7 15,5 15,3 21,9 20,1 26,1 22,7 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 1547 1609 150,8 154,7 69,6 61,5 106,5 89,9 132,3 108,2 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 28 43 2,7 4,1 1,4 2,3 2,0 2,9 2,5 3,3 C50 Dojka Breast M Ž 10 1399 1,0 134,5 0,5 71,4 0,7 96,6 0,9 109,2 C53 Maternicni vrat Cervix uteri M Ž - 86 - 8,3 - 4,9 - 6,4 - 7,1 C54 Maternicno telo Corpus uteri M Ž - 351 - 33,7 - 15,9 - 22,7 - 26,0 C56 JajcnikOvary M Ž - 157 - 15,1 - 7,3 - 10,2 - 11,8 C61 Prostata Prostate M Ž 1595 - 155,5 - 74,9 - 110,6 - 135,5 - C62 Modo Testis M Ž 125 - 12,2 - 12,1 - 12,5 - 13,3 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 282 121 27,5 11,6 14,3 4,9 20,3 7,0 23,8 8,4 C67 Secni mehur Bladder M Ž 255 102 24,9 9,8 10,9 3,5 17,2 5,3 21,8 6,6 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 116 85 11,3 8,2 7,2 5,3 9,2 6,1 10,3 6,4 C73 Šcitnica Thyroid gland M Ž 47 164 4,6 15,8 2,9 11,0 3,7 13,5 4,2 14,9 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 33 24 3,2 2,3 2,9 2,7 3,1 2,6 3,4 2,8 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne M Ž 191 199 18,6 19,1 9,6 8,6 13,7 12,1 16,7 14,4 C90 neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 83 58 8,1 5,6 3,9 2,4 5,8 3,3 7,0 3,8 C91-C95 Levkemije Leukaemias M Ž 193 136 18,8 13,1 11,8 5,8 14,9 7,8 17,1 9,1 * SSS - starostno standardizirana incidencna stopnja na 100.000 ASR - age standardized incidence rate per 100,000 Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2017. Table 3: Cancer incidence by age and by sex with crude rate (CR) per 100,000 population and cumulative rate (CR), Slovenia 2017. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C00 - C96 Vse lokacije All sites M+Ž M Ž 14987 7974 7013 25 18 7 8 3 5 11 8 3 28 14 14 44 29 15 64 37 27 130 68 62 228 77 151 370 131 239 573 206 367 872 402 470 1335 689 646 2007 1168 839 2283 1421 862 1973 1181 792 2044 1147 897 1653 848 805 1339 527 812 725,4 777,2 674,2 39,9 46,1 34,6 C00 Ustnica Lip M Ž 20 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 2 0 4 0 3 0 5 3 1 2 4 3 1,9 1,0 0,1 0,0 C01 Baza jezika Base of tongue M Ž 32 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 2 0 9 1 10 1 3 0 3 0 1 0 1 1 1 1 3,1 0,4 0,2 0,0 C02 Jezik, drugi deliTongue, other & unspecified parts M Ž 18 13 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0 2 0 0 1 2 2 5 1 4 1 2 3 0 1 0 2 2 0 1,8 1,2 0,1 0,1 C03 Dlesen Gum M Ž 6 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 2 1 1 0 0 0 1 1 1 2 0,6 0,7 0,0 0,0 C04 Ustno dno Floor of mouth M Ž 19 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 3 0 3 1 2 0 5 2 4 1 1 0 0 0 0 0 0 0 1,9 0,4 0,1 0,0 C05 Nebo Palate M Ž 14 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 0 5 1 4 3 2 1 0 2 0 0 0 1 0 0 1,4 0,9 0,1 0,1 C06 Usta, drugi deliMouth, other & unspecified parts M Ž 17 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 3 1 5 0 3 1 1 0 1 2 2 0 0 0 1 0 1,7 0,4 0,1 0,0 C07 Parotidna žleza Parotid gland M Ž 6 8 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 2 0 1 2 1 0 0 0 1 3 1 0 0,6 0,8 0,0 0,0 Druge in neopredeljene velike C08 žleze slinavke Other & unspecified major salivary M Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0,2 0,1 0,0 0,0 glands C09 Tonzila Tonsil M Ž 42 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 4 0 3 1 8 0 9 2 9 1 5 0 0 0 1 2 0 0 4,1 0,7 0,3 0,0 C10 Orofarinks Oropharynx M Ž 22 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 2 0 3 0 4 1 6 0 3 1 0 0 1 0 0 0 2,1 0,2 0,2 0,0 C11 Nazofarinks Nasopharynx M Ž 6 3 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 2 0 1 1 1 0 1 0 0 0 0 0 0 0 0,6 0,3 0,0 0,0 C12 Piriformni sinus Pyriform sinus M Ž 34 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 5 1 3 3 8 1 5 0 4 1 7 0 1 2 0 0 3,3 0,8 0,2 0,0 C13 HipofarinksHypopharynx M Ž 26 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 5 1 7 3 6 0 1 1 2 0 1 0 2 0 2,5 0,5 0,2 0,0 Druga in slabo opredeljena mesta na ustnici, v ustni votlini C14 in farinksu Other and ill-defined sites M Ž 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0,1 0 0,0 0 in the lip, oral cavity and pharynx C15 Požiralnik Oesophagus M Ž 66 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 4 0 10 0 13 1 17 5 8 4 4 6 4 2 3 3 6,4 2,1 0,4 0,1 C16 Želodec Stomach M Ž 251 174 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 1 2 3 2 5 10 2 20 11 38 13 33 23 38 21 44 28 36 28 27 37 24,5 16,7 1,2 0,7 C17 Tanko crevo Small intestine M Ž 28 20 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 4 0 2 0 2 1 6 3 4 5 3 1 4 6 2 1 0 3 2,7 1,9 0,2 0,1 C18 Debelo crevo Colon M Ž 453 330 0 0 0 0 0 0 0 1 0 0 1 0 0 2 3 2 7 5 9 15 27 24 24 19 57 26 73 37 75 51 65 50 72 58 40 40 44,2 31,7 2,4 1,5 C19 Rektosigmoidna zveza Rectosigmoid junction M Ž 62 56 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 2 1 3 3 4 6 1 5 4 11 4 12 6 9 10 11 11 2 10 6,0 5,4 0,4 0,2 C20 Rektum Rectum M Ž 275 145 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 5 8 3 6 3 18 9 37 7 47 25 39 16 31 19 36 21 33 17 17 19 26,8 13,9 1,5 0,7 C21 Anus in analni kanal Anus and anal canal M Ž 4 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 2 1 1 0 0 0 2 0 2 1 0 0 1 0,4 1,0 0,0 0,1 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 189 73 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 6 0 8 5 15 7 29 9 49 13 30 8 23 13 20 9 9 8 18,4 7,0 1,2 0,3 C23 Žolcnik Gallbladder M Ž 19 47 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 4 0 6 3 5 5 4 2 9 6 7 2 10 1,9 4,5 0,1 0,2 Drugi in neopredeljeni deli C24 biliarnega traktaBilliary tract, other and unspec- M Ž 66 63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 4 3 3 11 6 13 3 16 11 11 10 9 13 2 13 6,4 6,1 0,4 0,2 ified parts C25 Trebušna slinavka Pancreas M Ž 203 207 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 1 2 4 2 4 11 5 18 14 21 21 36 26 34 20 40 35 25 40 11 37 19,8 19,9 1,1 0,7 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Druga in slabo opredeljena mesta C26 v prebavnih organihOther and ill-defined digestive organs M Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0,2 0,1 0,0 0,0 C30 Nosna votlina in srednje uhoNasal cavity and middle ear M Ž 7 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 2 0 0 0 0 0 2 0 1 0 1 1 0,7 0,2 0,0 0,0 C31 Obnosni sinusi Accessory sinuses M Ž 5 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 2 0 2 1 0 0 0 1 0 1 0 0 1 0,5 0,5 0,0 0,0 C32 Grlo Larynx M Ž 87 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 1 4 0 9 2 22 1 24 1 9 1 12 1 4 0 1 0 8,5 0,7 0,6 0,0 C33 SapnikTrachea M Ž 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2 0 1 0 0 0 1 0 0 0 0,5 0,1 0,0 0,0 C34 Sapnica in pljucaBronchus and lung M Ž 882 569 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 3 6 2 6 12 49 25 103 78 154 104 190 110 137 77 113 80 73 44 50 33 86,0 54,7 5,5 3,2 C37 Timus Thymus M Ž 4 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 2 1 1 1 1 1 0 1 0 0 0 0 0,4 0,6 0,0 0,0 C38 Srce, mediastinum, plevraHeart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih M Ž M 2 3 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0,2 0,3 0,0 0,0 0,0 0,0 C39 Other and ill-defined sites in the respiratory system and intrathoracic organs Kosti, sklepni hrustanec Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,0 0,0 C40 udov Bone and articular cartilage of limbs Kosti, sklepni hrustanec, M Ž 5 4 0 0 0 1 0 0 2 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0,5 0,4 0,0 0,0 C41 drugjeBone and articular cartilage of other and unspecified parts M Ž 5 7 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 1 1 0 1 2 0 0 1 0 0 1 0 0,5 0,7 0,0 0,1 C43 Maligni melanom kože Malignant melanoma of skin M Ž 300 278 0 0 0 1 0 0 0 2 2 1 1 4 4 9 10 12 15 21 16 28 21 27 24 31 45 20 45 26 38 31 39 25 22 17 18 23 29,2 26,7 1,8 1,6 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 1547 1609 0 0 0 0 0 0 0 0 3 0 5 3 8 7 15 26 30 56 49 63 67 93 107 108 158 155 229 160 212 201 268 241 238 237 158 259 150,8 154,7 7,5 6,8 C45 Mezoteliom Mesothelioma M Ž 35 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 1 7 0 8 2 3 2 5 2 7 1 2 0 3,4 0,8 0,2 0,0 C46 Kaposijev sarkom Kaposi’s sarcoma Periferni živci in avtonomno M Ž 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C47 živcevjePeripheral nerves and autonomic nervous system M Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0,2 0,1 0,0 0,0 C48 Peritonej in retroperitonej Retroperitoneum and peritoneum M Ž 6 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 2 0 3 1 5 0 2 1 3 3 1 0 1 0,6 1,7 0,0 0,1 C49 Drugo vezivno in mehko tkivo Other connective and soft tissue M Ž 22 25 0 1 0 0 0 0 0 0 0 1 0 0 0 1 1 3 1 1 1 1 3 3 1 2 2 0 4 2 4 2 3 2 1 3 1 3 2,1 2,4 0,1 0,1 C50 Dojka Breast M Ž 10 1399 0 0 0 0 0 0 0 0 0 1 0 4 0 10 1 50 0 86 1 137 0 135 0 164 2 198 3 177 1 115 2 123 0 111 0 88 1,0 134,5 0,1 7,9 C51 Žensko zunanje spolovilo Vulva M Ž - 58 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 5 - 3 - 6 - 12 - 9 - 10 - 11 - 5,6 - 0,2 C52 Nožnica Vagina M Ž - 12 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 0 - 1 - 0 - 0 - 2 - 2 - 1 - 0 - 1 - 2 - 2 - 1,2 - 0,1 C53 Maternicni vrat Cervix uteri M Ž - 86 - 0 - 0 - 0 - 0 - 0 - 0 - 6 - 13 - 3 - 8 - 8 - 10 - 8 - 10 - 5 - 1 - 4 - 10 - 8,3 - 0,5 C54 Maternicno telo Corpus uteri M Ž - 351 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 3 - 7 - 14 - 31 - 53 - 57 - 48 - 45 - 50 - 19 - 23 - 33,7 - 2,0 C55 Maternica, neopredeljenoUterus, unspecified M Ž - 20 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 2 - 1 - 3 - 1 - 2 - 2 - 4 - 1 - 3 - 1,9 - 0,1 C56 JajcnikOvary Drugi in neopredeljeni ženski M Ž - 157 - 0 - 0 - 0 - 0 - 1 - 0 - 1 - 3 - 2 - 11 - 14 - 17 - 20 - 25 - 21 - 18 - 13 - 11 - 15,1 - 0,9 C57 spolni organiOther and unspecified parts of female genital organs M Ž - 25 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 5 - 6 - 2 - 6 - 1 - 2 - 2 - 2,4 - 0,2 Nadaljevanje —> Continued —> 35 Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ C58 Posteljica Placenta M Ž - 1 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0,1 - 0,0 C60 Penis Penis M Ž 12 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 2 - 1 - 2 - 1 - 1 - 1 - 4 - 0 - 1,2 - 0,1 - C61 Prostata Prostate M Ž 1595 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 9 - 56 - 144 - 283 - 393 - 315 - 229 - 113 - 53 - 155,5 - 10,6 - C62 Modo Testis Drugi in neopredeljeni moški M Ž 125 - 2 - 0 - 0 - 2 - 16 - 17 - 28 - 20 - 14 - 15 - 5 - 2 - 4 - 0 - 0 - 0 - 0 - 0 - 12,2 - 0,9 - C63 spolni organiOther and unspecified male genital organs M Ž 3 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 0 - 1 - 0 - 0 - 0 - 0 - 0 - 0,3 - 0,0 - C64 Ledvica razen meha Kidney, except renal pelvis M Ž 261 104 1 0 0 0 0 0 0 0 0 0 1 0 0 1 2 1 7 1 15 6 18 7 33 5 48 15 46 16 30 13 28 14 18 18 14 7 25,4 10,0 1,6 0,5 C65 Ledvicni meh Renal pelvis M Ž 21 17 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 2 0 1 1 2 3 4 0 4 3 3 0 4 5 1 3 2,0 1,6 0,1 0,1 C66 Secevod Ureter M Ž 9 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 1 1 2 0 3 3 0 1 0,9 0,6 0,0 0,0 C67 Secni mehur Bladder Drugi in neopredeljeni secni M Ž 255 102 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 0 5 3 14 3 15 1 28 15 29 15 39 14 52 18 32 13 39 19 24,9 9,8 1,2 0,4 C68 organiOther and unspecified urinary organs M Ž 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0,1 0 0,0 C69 Oko in ocesni adneksi Eye and adnexa M Ž 9 11 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 1 1 2 1 2 0 2 1 1 0 0 3 2 0,9 1,1 0,0 0,1 C70 MeningeMeninges M Ž 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0,1 0,2 0,0 0,0 C71 MožganiBrain Hrbtni mozeg, možganski živci in M Ž 114 81 3 4 0 2 0 0 0 1 1 0 2 3 2 0 6 1 5 4 11 4 15 6 13 8 11 8 13 10 9 7 13 4 7 11 3 8 11,1 7,8 0,7 0,5 C72 drugi deli CŽSSpinal cord, cranial nerves and other parts of CNS M Ž 1 2 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,1 0,2 0,0 0,0 C73 Šcitnica Thyroid gland M Ž 47 164 0 0 0 0 0 0 1 1 0 5 0 6 2 10 3 7 2 10 8 25 2 12 7 24 8 17 6 19 4 14 3 9 1 5 0 0 4,6 15,8 0,3 1,1 C74 Nadledvicna žleza Adrenal gland Druge endokrine žleze in sorodne M Ž 8 5 2 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 2 0 0 1 0 1 0 0 0 0 0 1 1 1 0 0 1 0 0,8 0,5 0,0 0,0 C75 strukture Other endocrine glands and related structures M Ž 4 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0,4 0 0,0 0 C76 Druga in slabo opredeljena mestaOther and ill-defined sites Metastaza in neopredeljena M Ž 1 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 1 1 0 0 0 1 0 2 0 3 0,1 1,0 0,0 0,0 C77 maligna neoplazma bezgavkMetastasis and unspecified malignant neoplasm of lymph nodes Metastaze dihal in M Ž 24 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 0 3 1 8 2 1 1 2 1 4 0 0 1 3 0 2,3 0,6 0,1 0,0 C78 prebavilMetastases of respiratory and digestive organs M Ž 23 42 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 2 4 0 2 2 5 1 2 4 2 8 7 24 2,2 4,0 0,1 0,0 C79 Metastaze, drugjeMetastases of other sites Maligna neoplazma brez M Ž 11 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 2 6 1 1 0 0 1 2 1 0 0 1,1 0,6 0,1 0,0 C80 opredeljenega mestaMalignant neoplasm withoutspecification of site M Ž 47 64 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 2 1 1 0 3 3 2 5 5 5 7 8 8 6 3 6 10 7 14 5 9 4,6 6,2 0,2 0,2 C81 Hodgkinov limfomHodgkin’s lymphoma Folikularni ne-Hodgkinov M Ž 33 24 0 0 0 0 1 1 3 2 2 5 4 3 3 3 3 3 3 2 1 1 2 0 2 0 0 0 3 0 2 1 2 1 2 1 0 1 3,2 2,3 0,2 0,2 C82 limfom Follicular non-Hodgkin’s lymphoma M Ž 45 64 0 0 0 0 0 0 1 0 0 0 1 0 2 1 0 3 3 8 0 1 2 7 3 5 7 6 3 13 4 7 9 7 6 4 4 2 4,4 6,2 0,2 0,4 C83 Difuzni ne-Hodgkinov limfomDiffuse non-Hodgkin’s lymphoma M Ž 122 113 0 0 0 0 0 0 1 1 1 0 0 1 3 2 2 1 2 1 7 2 3 5 6 6 17 12 12 18 16 9 23 27 23 12 6 16 11,9 10,9 0,6 0,5 Nadaljevanje —> Continued —> Tabela 3: Nadaljevanje. Table 3: Continued. Šifra MKB Primarna lokacija Spol Vse starosti Starost / Age GS KS 0-74ICD code Primary site Sex All ages 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Limfomi celic T in kožni limfom C84 celic T Peripheral and cutaneous T-cell lymphomas Druge in neopredeljene vrste M Ž 13 13 1 0 0 0 0 0 0 1 1 0 0 0 2 0 0 0 1 0 1 0 0 0 1 1 2 0 1 2 1 5 0 2 1 1 1 1 1,3 1,2 0,1 0,1 C85 ne-Hodgkinovega limfomaOther and unspecified types ofnon-Hodgkin’s lymphoma Maligne imunoproliferativne M Ž 11 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 0 1 2 0 2 2 2 2 4 0 0 2 1,1 0,9 0,0 0,0 C88 bolezni Malignant immunoproliferativediseases Difuzni plazmocitom in maligne M Ž 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0,2 0,1 0,0 0,0 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms M Ž 83 58 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1 0 2 1 1 7 5 7 4 13 12 16 8 9 2 14 6 7 10 7 7 8,1 5,6 0,5 0,3 C91.0 Limfoblastna levkemija Lymphocytic leukaemia, acute M Ž 19 7 6 2 2 1 3 0 1 0 0 0 0 0 1 0 1 0 0 0 1 0 2 1 0 1 0 1 1 0 0 0 0 0 1 0 0 1 1,9 0,7 0,2 0,0 C91.1- Limfaticna levkemija, druga M 75 0 0 0 0 0 1 0 0 1 4 5 6 10 9 11 14 8 6 7,3 0,4 C91.9 Lymphoid leukaemia, other Ž 47 0 0 0 0 0 0 0 0 1 1 3 0 5 4 7 8 5 13 4,5 0,2 C92 Mieloicna levkemija Myeloid leukaemia M Ž 78 60 1 0 0 0 1 1 0 0 1 0 1 0 3 0 1 4 1 3 2 4 1 3 5 6 10 4 13 7 16 7 9 3 7 8 6 10 7,6 5,8 0,5 0,3 C93 Monocitna levkemija Monocytic leukaemia Druge opredeljene M Ž 6 5 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 1 0 0 0 1 1 0 0 1 0 0 3 1 0 0,6 0,5 0,0 0,0 C94 levkemije Other leukaemias of specified cells Levkemija z neopredeljenim M Ž 12 11 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 2 0 1 1 1 2 3 0 2 2 1 2 1 3 1,2 1,1 0,1 0,0 C95 celicnim tipomLeukaemia, unspecified cell type Druge in neopredeljene maligneneoplazme limfaticnega, krvot- M Ž 3 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 1 1 2 0 1 0,3 0,6 0,0 0,0 C96 vornega ali sorodnega tkivaOther and unspecified malignantneoplasms of lymphoid, haematopoietic and related tissue M Ž 94 87 1 0 1 0 0 0 0 1 0 0 1 0 2 1 0 2 2 3 1 3 4 5 0 3 14 6 9 8 12 11 24 17 15 10 8 17 9,2 8,4 0,4 0,3 Zgoraj neupoštevani: Not included above: D03 Melanom, in situ Melanoma, in situ M Ž 125 149 0 0 0 0 0 0 0 0 1 1 1 4 2 5 5 12 8 10 6 12 14 13 7 9 15 12 18 20 12 15 13 20 14 12 9 4 12,2 14,3 0,7 0,9 D05 Dojka, in situ Breast, in situ M Ž 1 170 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 8 0 21 0 29 0 28 0 30 0 36 1 10 0 3 0 2 0 2 0,1 16,3 0,0 1,2 D06 Maternicni vrat, in situ (CIN III) Cervix uteri, in situ M Ž - 1123 - 0 - 0 - 0 - 0 - 92 - 193 - 227 - 200 - 125 - 85 - 73 - 45 - 41 - 22 - 9 - 10 - 1 - 0 - 108,0 - 8,4 D09.0 Secni mehur, in situ Bladder, in situ Meninge, benigna neoplazma in neoplazma M Ž 193 63 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 4 1 8 2 16 4 21 8 42 10 30 12 33 8 22 9 15 7 18,8 6,1 1,1 0,3 D32.0, negotovega znacaja M 39 0 0 0 0 1 0 0 2 1 2 3 2 4 5 6 6 4 3 3,8 0,2 D42.0 Benign neoplasm and neoplasm of uncertain behaviour of meninges Ž 114 0 0 0 0 0 2 4 2 3 9 9 10 18 14 8 15 11 9 11,0 0,6 D33.0- Možgani, benigna neoplazma M 3 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0,3 0,0 D33.2 Benign neoplasm of brain Jajcnik, neoplazma Ž 2 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0,2 0,0 D39.1 negotovega znacajaOvary, neoplasm of uncertain behavior M Ž - 71 - 0 - 0 - 1 - 0 - 0 - 4 - 2 - 3 - 7 - 7 - 6 - 8 - 13 - 8 - 3 - 4 - 3 - 2 - 6,8 - 0,5 D43.0- Možgani, neopredeljeno M 13 0 1 0 1 0 1 2 0 0 0 0 0 0 1 2 2 1 2 1,3 0,1 D43.2 CNS, uncertain or unknown Ž 9 0 1 1 1 0 1 0 1 0 0 1 0 0 0 1 2 0 0 0,9 0,1 Tabela 4a: Incidenca mikroskopsko (histološko in citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2017. Table 4a: Incidence of microscopicaly (histologically and cytologically) confirmed cancer cases by morphological type, Slovenia 2017. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 Vse vrste / All types 13175 30 36 31 13 23 23 21 14 3 49 24 9 42 31 0 83 413 48 765 Small cell carcinoma 220 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 Non-small cell carcinoma 89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1509 30 36 29 12 23 19 20 1 1 48 22 8 42 30 0 60 4 0 0 Basal cell carcinoma 2620 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 372 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6881 0 0 1 0 0 3 0 10 1 0 1 0 0 0 0 20 368 35 756 Other specified carcinomas 122 0 0 0 1 0 1 1 2 0 1 0 0 0 0 0 0 3 0 0 Carcinoma, unspecified 169 0 0 0 0 0 0 0 0 1 0 1 1 0 1 0 2 9 0 8 Malignant thymoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 613 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 83 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 27 13 0 Malignant fibroepithelial tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 76 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant trophoblastic tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 168 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C19 C20 C21 C22 C23 C24 C25 C26 C30 C31 C32 C33 C34 C37 C38 C39 C40 C41 C43 Vse vrste / All types 13175 112 412 13 150 48 87 270 2 9 10 94 6 1353 10 4 0 9 11 578 Small cell carcinoma 220 0 0 0 1 0 1 1 0 0 0 0 2 200 0 0 0 0 0 0 Non-small cell carcinoma 89 0 0 0 0 0 0 0 0 0 0 0 0 88 0 0 0 0 0 0 Squamous cell carcinoma 1509 0 1 10 0 0 0 0 0 4 6 94 3 340 1 0 0 0 0 0 Basal cell carcinoma 2620 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 372 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6881 110 404 2 147 39 81 240 0 2 1 0 1 657 0 0 0 0 0 0 Other specified carcinomas 122 1 0 0 1 5 0 7 0 0 0 0 0 38 0 0 0 0 0 0 Carcinoma, unspecified 169 1 6 0 1 3 5 21 0 0 0 0 0 25 0 0 0 0 0 0 Malignant thymoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 613 0 1 1 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 578 Fibrosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Liposarcoma 16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 Angiosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Kaposi sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 Chondrosarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 6 0 Ewing sarcoma/PNET 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 Other specified sarcomas 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 0 0 0 0 0 0 0 0 0 1 0 0 2 0 1 0 0 1 0 Malignant complex mixed and stromal tumors 83 0 0 0 0 1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 Malignant fibroepithelial tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 76 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other malignant germ cell tumors 52 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 Malignant trophoblastic tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 168 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 7 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Malignant tumor, unspecified 12 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 Nadaljevanje —> Continued —> 39 Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C44 C45 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C60 C61 C62 Vse vrste / All types 13175 3147 43 0 3 24 47 1398 58 12 85 349 14 147 24 1 12 1545 125 Small cell carcinoma 220 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 Non-small cell carcinoma 89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Squamous cell carcinoma 1509 492 0 0 0 0 0 0 49 9 67 0 0 1 0 0 12 0 0 Basal cell carcinoma 2620 2615 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 372 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 Adenocarcinoma 6881 26 0 0 0 13 0 1355 2 1 16 288 0 128 23 0 0 1534 0 Other specified carcinomas 122 0 0 0 0 0 0 9 0 0 0 34 0 3 0 0 0 1 0 Carcinoma, unspecified 169 2 0 0 0 0 0 33 0 0 0 3 0 3 1 0 0 3 0 Malignant thymoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant melanoma 613 0 0 0 0 0 0 0 2 1 0 0 0 0 0 0 0 0 0 Fibrosarcoma 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 11 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 16 0 0 0 0 2 13 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 19 1 0 0 0 2 9 0 0 0 0 0 5 0 0 0 0 0 0 Rhabdomyosarcoma 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 11 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 5 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 4 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 Sarcoma, unspecified 21 0 0 0 0 3 12 0 0 0 0 0 1 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 83 0 0 0 0 1 1 0 0 0 2 22 8 3 0 0 0 0 0 Malignant fibroepithelial tumors 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 43 0 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 Dysgerminoma and seminoma 76 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 75 Other malignant germ cell tumors 52 0 0 0 0 2 0 0 0 0 0 1 0 2 0 0 0 0 44 Malignant trophoblastic tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 6 Malignant gliomas 168 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 12 0 0 0 0 1 1 0 0 1 0 0 0 1 0 0 0 0 0 Nadaljevanje —> Continued —> Tabela 4a: Nadaljevanje. Table 4a: Continued. Histološka vrsta Skupaj Primarna lokacija (šifra MKB) Histologic type All Sites Primary site (ICD code) C00-C80 C63 C64 C65 C66 C67 C68 C69 C70 C71 C72 C73 C74 C75 C76 C77 C78 C79 C80 Vse vrste / All types 13175 3 326 36 13 351 1 20 3 168 3 211 13 4 7 28 27 14 77 Small cell carcinoma 220 0 0 0 0 6 0 0 0 0 0 0 0 0 1 2 0 2 0 Non-small cell carcinoma 89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Squamous cell carcinoma 1509 0 0 1 0 7 0 2 0 0 0 0 0 0 0 17 0 1 7 Basal cell carcinoma 2620 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Transitional cell carcinoma 372 0 0 31 12 322 1 0 0 0 0 0 0 0 0 0 0 0 0 Adenocarcinoma 6881 0 321 0 0 2 0 0 0 0 0 203 3 2 2 5 21 8 49 Other specified carcinomas 122 0 0 0 0 1 0 0 0 0 0 8 1 0 0 3 0 1 0 Carcinoma, unspecified 169 0 4 3 1 13 0 0 0 0 0 0 0 0 2 0 5 0 11 Malignant thymoma 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant paraganglioma/pheochromocytoma 7 0 0 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 0 Malignant melanoma 613 0 0 0 0 0 0 17 1 0 0 0 0 0 0 1 0 2 6 Fibrosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Fibrohistiocytic sarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Liposarcoma 16 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Leiomyosarcoma 19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Rhabdomyosarcoma 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Synovial sarcoma 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Angiosarcoma 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Kaposi sarcoma 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Osteosarcoma 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Chondrosarcoma 11 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Ewing sarcoma/PNET 5 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Other specified sarcomas 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sarcoma, unspecified 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant complex mixed and stromal tumors 83 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Malignant fibroepithelial tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant mesothelioma 43 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gonadal stromal tumors 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Dysgerminoma and seminoma 76 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 Other malignant germ cell tumors 52 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 Malignant trophoblastic tumors 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant gliomas 168 0 0 0 0 0 0 0 0 166 2 0 0 0 0 0 0 0 0 Malignant neuroepithelial tumors 7 0 0 0 0 0 0 1 0 2 0 0 2 0 0 0 0 0 0 Malignant meningioma 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 Malignant nerve sheath tumors 4 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 Other specified malignant tumors 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Malignant tumor, unspecified 12 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 3 Incidenca Incidence42Tabela 4b: Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2017. Table 4b: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumoursof Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2017. Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number Vse vrste All types Moški in ženske / Males and females 743 Moški / Males 405 Ženske / Females 338 9727, 9728, 9835, 9836, 9811-9818 Neoplazme nezrelih celic B 21Precursor lymphoid neoplasms B 9728, 9835,9811, 9813, 9815 Limfoblastni limfom B / levkemija B, BDO 21B lymphoblastic lymphoma / leukaemia, NOS 9729, 9837 Neoplazme nezrelih celic T 7Precursor lymphoid neoplasms T 9729, 9837 Limfoblastni limfom T / levkemija T 7T Lymphoblastic lymphoma / leukaemia 9591-9597, 96709699, 9712, 97319738, 9760-9764,9823, 9826,9833, 9940 Periferni B-celicni limfom / neoplazme zrelih celic B 623Mature B-cell neoplasms 9670, 9823 Kronicna limfaticna levkemija B / drobnocelicni limfocitni limfom 135Chronic lymphocytic leukaemia / small lymphocytic lymphoma 9689 Splenicni limfom robne cone 12Splenic marginal zone lymphoma 9591 Ne-Hodgkinovi limfomi, BDO; primarni vranicni limfom / levkemija, nerazvršceni; difuzni drobnocelicni limfom B rdece pulpe; posebnaoblika dlakastocelicne levkemije 16Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairycell leukaemia-variant 9940 Dlakastocelicna levkemija 3Hairy cell leukaemia 9671 Limfoplazmacitni limfom 7Lymphoplasmacytic lymphoma 9761 Waldenströmova makroglobulinemija 3Waldenström macroglobulinemia 9732, 9733 Multipli mielom 133Plasma cell myeloma 9731, 9734 Solitarni kostni in zunajkostni plazmacitom 8Solitary plasmacytoma of bone and extraosseous 9699, nodalni B-celicni limfom robne cone, nodalni 23Marginal zone B-cell lymphoma, nodal 9699, ekstranodalni B-celicni limfom robne cone, ekstranodalni 32Marginal zone B-cell lymphoma, extranodal 9690 Folikularni limfom, BDO 4Follicular lymphoma, NOS 9691, 9695 Folikularni limfom, gradus 1 in 2 36Follicular lymphoma, grade 1 and 2 9698 Folikularni limfom, gradus 3 14Follicular lymphoma, grade 3 9673 Limfom plašcnih celic 30Mantle cell lymphoma 9735 Plazmablastni limfom 1Plasmablastic lymphoma 9680 Difuzni velikocelicni limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kronicnim vnetjem; nerazvršceni B-celicni limfom, mejni primer med difuznim velikocelicnim limfomom B in Burkittovim limfomom 155Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCLof the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-celllymphoma, unclassifiable, with features intermediate between diffuselarge B-cell lymphoma and Burkitt lymphoma 9687 Burkittov limfom / levkemija 3Burkitt lymphoma / leukaemia Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number 9679 Primarni mediastinalni (timicni) velikocelicni limfom B 7Primary mediastinal (thymic) large B-cell lymphoma 9596 Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasicnega Hodgkinovega limfoma 1B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL Neoplazme zrelih celic T/NK 28Mature T- and NK-cell neoplasms 9827, 9831, 9834, 9948 Levkemicne neoplazme zrelih celic T/NK 2Leukaemic mature T- and NK-cell neoplasms 9831 Levkemija velikih granuliranih limfocitov T 2T-cell large granular lymphocytic leukemia 9700, 9701, 9708, 9709, 9716-9719 Neoplazme zrelih (ekstranodalnih) celic T/NK 10Mature (extranodal) T- and NK-cell neoplasms 9717 Limfom T z enteropatijo 2Enteropathy-associated T-cell lymphoma 9700 Fungoidna mikoza 4Mycosis fungoides 9701 Sézaryjev sindrom 1Sézary syndrome 9718 Primarne kožne CD30+ T-celicne limfoproliferativne bolezni 2Primary cutaneous CD30+ T-cell lymphoproliferative disorder 9709 Primarni kožni periferni limfomi T, redki tipi 1Primary cutaneous T-cell lymphoma, rare types 9702, 9705, 9714 Zrele (nodalne) neoplazme celic T/NK 16Mature (nodal) T- and NK-cell neoplasms 9702 Periferni limfom T (BDO- in ALK-negativen ALCL) 10Peripheral T-cell lymphoma (NOS and ALK negative ALCL) 9705 Angioimunoblastni limfom T 2Angioimmunoblastic T-cell lymphoma 9714 Anaplasticni velikocelicni limfom, ALK-pozitivni 4Anaplastic large cell lymphoma, ALK positive 9650-9667 Hodgkinov limfom (HL) 57Hodgkin lymphoma (HL) 9659 HL z nodularno limfocitno predominanco 2Nodular lymphocyte predominant HL 9650 Klasicni HL 4Classical HL 9663, 9664, 9667 Klasicni HL, tip nodularne skleroze 31Nodular sclerosis classical HL 9651 Z limfociti bogat klasicni HL 5Lymphocyte-rich classical HL 9652 Mešanocelicni tip klasicnega HL 14Mixed cellularity classical HL 9653 Klasicni HL, tip limfocitne deplecije 1Lymphocyte-depleted classical HL 9590, 9832 Neopredeljeni limfomi / levkemije 3Unspecified lymphoma / leukemia 9590 Maligni limfom, BDO 3Malignant lymphoma, NOS 9750-9759 Neoplazme histiocitov in dendriticnih celic 4Histiocytic and dendritic cell neoplasms 9751 Histiocitoza Langerhansovih celic, NOS 3Langerhans cell histiocytosis, NOS 9757 Sarkom interdigitatnih dendriticnih celic 1Interdigitating dendritic cell sarcoma 42Tabela 4b: Incidenca malignih neoplazem limfaticnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2008, Slovenija 2017. Table 4b: Incidence of malignant neoplasms of lymphoid tissue according to 2008 version of Classification of Tumoursof Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2017. Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number Vse vrste All types Moški in ženske / Males and females 743 Moški / Males 405 Ženske / Females 338 9727, 9728, 9835, 9836, 9811-9818 Neoplazme nezrelih celic B 21Precursor lymphoid neoplasms B 9728, 9835,9811, 9813, 9815 Limfoblastni limfom B / levkemija B, BDO 21B lymphoblastic lymphoma / leukaemia, NOS 9729, 9837 Neoplazme nezrelih celic T 7Precursor lymphoid neoplasms T 9729, 9837 Limfoblastni limfom T / levkemija T 7T Lymphoblastic lymphoma / leukaemia 9591-9597, 96709699, 9712, 97319738, 9760-9764,9823, 9826,9833, 9940 Periferni B-celicni limfom / neoplazme zrelih celic B 623Mature B-cell neoplasms 9670, 9823 Kronicna limfaticna levkemija B / drobnocelicni limfocitni limfom 135Chronic lymphocytic leukaemia / small lymphocytic lymphoma 9689 Splenicni limfom robne cone 12Splenic marginal zone lymphoma 9591 Ne-Hodgkinovi limfomi, BDO; primarni vranicni limfom / levkemija, nerazvršceni; difuzni drobnocelicni limfom B rdece pulpe; posebnaoblika dlakastocelicne levkemije 16Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairycell leukaemia-variant 9940 Dlakastocelicna levkemija 3Hairy cell leukaemia 9671 Limfoplazmacitni limfom 7Lymphoplasmacytic lymphoma 9761 Waldenströmova makroglobulinemija 3Waldenström macroglobulinemia 9732, 9733 Multipli mielom 133Plasma cell myeloma 9731, 9734 Solitarni kostni in zunajkostni plazmacitom 8Solitary plasmacytoma of bone and extraosseous 9699, nodalni B-celicni limfom robne cone, nodalni 23Marginal zone B-cell lymphoma, nodal 9699, ekstranodalni B-celicni limfom robne cone, ekstranodalni 32Marginal zone B-cell lymphoma, extranodal 9690 Folikularni limfom, BDO 4Follicular lymphoma, NOS 9691, 9695 Folikularni limfom, gradus 1 in 2 36Follicular lymphoma, grade 1 and 2 9698 Folikularni limfom, gradus 3 14Follicular lymphoma, grade 3 9673 Limfom plašcnih celic 30Mantle cell lymphoma 9735 Plazmablastni limfom 1Plasmablastic lymphoma 9680 Difuzni velikocelicni limfom B (DLBCL), BDO; primarni DLBCL CŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kronicnim vnetjem; nerazvršceni B-celicni limfom, mejni primer med difuznim velikocelicnim limfomom B in Burkittovim limfomom 155Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCLof the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-celllymphoma, unclassifiable, with features intermediate between diffuselarge B-cell lymphoma and Burkitt lymphoma 9687 Burkittov limfom / levkemija 3Burkitt lymphoma / leukaemia Šifra ICD-O-3 ICD-O-3 code Histološka vrsta Histology type Število Number 9679 Primarni mediastinalni (timicni) velikocelicni limfom B 7Primary mediastinal (thymic) large B-cell lymphoma 9596 Neopredeljivi limfom s celicami B, z lastnostmi difuznega limfoma z velikimi celicami B in klasicnega Hodgkinovega limfoma 1B-cell lymphoma, unclassifiable, with features between DLBCL and classical HL Neoplazme zrelih celic T/NK 28Mature T- and NK-cell neoplasms 9827, 9831, 9834, 9948 Levkemicne neoplazme zrelih celic T/NK 2Leukaemic mature T- and NK-cell neoplasms 9831 Levkemija velikih granuliranih limfocitov T 2T-cell large granular lymphocytic leukemia 9700, 9701, 9708, 9709, 9716-9719 Neoplazme zrelih (ekstranodalnih) celic T/NK 10Mature (extranodal) T- and NK-cell neoplasms 9717 Limfom T z enteropatijo 2Enteropathy-associated T-cell lymphoma 9700 Fungoidna mikoza 4Mycosis fungoides 9701 Sézaryjev sindrom 1Sézary syndrome 9718 Primarne kožne CD30+ T-celicne limfoproliferativne bolezni 2Primary cutaneous CD30+ T-cell lymphoproliferative disorder 9709 Primarni kožni periferni limfomi T, redki tipi 1Primary cutaneous T-cell lymphoma, rare types 9702, 9705, 9714 Zrele (nodalne) neoplazme celic T/NK 16Mature (nodal) T- and NK-cell neoplasms 9702 Periferni limfom T (BDO- in ALK-negativen ALCL) 10Peripheral T-cell lymphoma (NOS and ALK negative ALCL) 9705 Angioimunoblastni limfom T 2Angioimmunoblastic T-cell lymphoma 9714 Anaplasticni velikocelicni limfom, ALK-pozitivni 4Anaplastic large cell lymphoma, ALK positive 9650-9667 Hodgkinov limfom (HL) 57Hodgkin lymphoma (HL) 9659 HL z nodularno limfocitno predominanco 2Nodular lymphocyte predominant HL 9650 Klasicni HL 4Classical HL 9663, 9664, 9667 Klasicni HL, tip nodularne skleroze 31Nodular sclerosis classical HL 9651 Z limfociti bogat klasicni HL 5Lymphocyte-rich classical HL 9652 Mešanocelicni tip klasicnega HL 14Mixed cellularity classical HL 9653 Klasicni HL, tip limfocitne deplecije 1Lymphocyte-depleted classical HL 9590, 9832 Neopredeljeni limfomi / levkemije 3Unspecified lymphoma / leukemia 9590 Maligni limfom, BDO 3Malignant lymphoma, NOS 9750-9759 Neoplazme histiocitov in dendriticnih celic 4Histiocytic and dendritic cell neoplasms 9751 Histiocitoza Langerhansovih celic, NOS 3Langerhans cell histiocytosis, NOS 9757 Sarkom interdigitatnih dendriticnih celic 1Interdigitating dendritic cell sarcoma Tabela 4c: Incidenca ne-Hodgkinovih limfomov po lokaciji, Slovenija 2017. Table 4c: Incidence of non-Hodgkin´s malignant lymphomas by cancer site, Slovenia 2017. Šifra MKB-8 Primarna lokacija Vse starosti ICD-8 code Primary site All ages Vsi NHL All NHL 390 142 Slinavke Salivary glands 5 145 Usta, drugo Mouth, other parts 2 146 Orofarinks Oropharynx 11 147 Epifarinks Epipharynx 1 151 Želodec Stomach 22 152 Tanko crevo Small intestine 4 153 Debelo crevo Colon 6 157 Trebušna slinavka Pancreas 1 160 Nos, obnosne votline, drugo Nos, obnosne votline, drugo 1 162 Sapnik, sapnica, pljuca Trachea, bronchus, lung 5 163 Plevra, mediastinum, drugo Pleura, mediastinum, etc. 3 170 Kosti Bone 3 171 Mehka tkiva Soft tissues 1 173 Koža, drugi malignomi Skin, other malignancies 14 174 Dojka Breast 2 182 Maternica, telo, drugo Uterus, corpus, etc. 1 183 Jajcnik, jajcevod, drugo Ovary, Fallopian tube, other 1 186 Modo Testis 1 188 Mehur Bladder 1 190 Oko Eye 6 191 Možgani Brain 13 193 Šcitnica Thyroid 2 202 Bezgavke Lymph nodes 284 Tabela 5: Incidenca raka po stadiju, Slovenija 2017. Table 5: Cancer incidence by stage, Slovenia 2017. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C00-C80 Vse lokacije / All sites Moški in ženske / Males and females Moški / Males Ženske / Females 12744 6765 5979 7704 3995 3709 60,5 59,1 62,0 3384 1868 1516 26,6 27,6 25,4 2537 1347 1190 19,9 19,9 19,9 261,0 168,0 93,0 2,0 2,5 1,6 C00 Ustnica / Lip 30 28 93,3 2 6,7 0 0,0 0 0,0 C01 Baza jezika / Base of tongue 36 5 13,9 29 80,6 2 5,6 0 0,0 C02 Jezik, drugi deli / Tongue, other & unspecified parts 31 15 48,4 16 51,6 0 0,0 0 0,0 C03 Dlesen / Gum 13 3 - 10 - 0 - 0 - C04 Ustno dno / Floor of mouth 23 7 30,4 15 65,2 1 4,3 0 0,0 C05 Nebo / Palate 23 6 26,1 16 69,6 1 4,3 0 0,0 C06 Usta, drugi deli / Mouth, other & unspecified parts 21 3 14,3 18 85,7 0 0,0 0 0,0 C07 Parotidna žleza / Parotid gland 14 6 - 7 - 1 - 0 - C08 Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands 3 0 - 2 - 1 - 0 - C09 Tonzila / Tonsil 49 9 18,4 39 79,6 1 2,0 0 0,0 C10 Orofarinks / Oropharynx 24 3 12,5 20 83,3 1 4,2 0 0,0 C11 Nazofarinks / Nasopharynx 9 0 - 7 - 2 - 0 - C12 Piriformni sinus / Pyriform sinus 42 5 11,9 34 81,0 3 7,1 0 0,0 C13 Hipofarinks / Hypopharynx 31 2 6,5 27 87,1 2 6,5 0 0,0 C14 Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx 1 0 - 1 - 0 - 0 - C15 Požiralnik / Oesophagus 88 5 5,7 47 53,4 28 31,8 8 9,1 C16 Želodec / Stomach 425 75 17,6 151 35,5 174 40,9 25 5,9 C17 Tanko crevo / Small intestine 48 15 31,3 18 37,5 15 31,3 0 0,0 C18 Debelo crevo / Colon 783 169 21,6 398 50,8 195 24,9 21 2,7 C19 Rektosigmoidna zveza / Rectosigmoid junction 118 22 18,6 58 49,2 36 30,5 2 1,7 C20 Rektum / Rectum 420 73 17,4 234 55,7 103 24,5 10 2,4 C21 Anus in analni kanal / Anus and anal canal 14 5 - 7 - 2 - 0 - C22 Jetra in intrahepaticni vodi / Liver and intrahepatic bile ducts 262 81 30,9 71 27,1 96 36,6 14 5,3 C23 Žolcnik / Gallbladder 66 15 22,7 15 22,7 34 51,5 2 3,0 C24 Drugi in neopredeljeni deli biliarnega trakta Billiary tract, other and unspecified parts 129 17 13,2 53 41,1 53 41,1 6 4,7 C25 Trebušna slinavka / Pancreas 410 35 8,5 150 36,6 209 51,0 16 3,9 C26 Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs 3 0 - 0 - 2 - 1 - C30 Nosna votlina in srednje uho / Nasal cavity and middle ear 9 2 - 7 - 0 - 0 - C31 Obnosni sinusi / Accessory sinuses 10 0 - 10 - 0 - 0 - C32 Grlo / Larynx 94 51 54,3 43 45,7 0 0,0 0 0,0 C33 Sapnik / Trachea 6 0 - 1 - 4 - 1 - C34 Sapnica in pljuca / Bronchus and lung 1451 245 16,9 450 31,0 740 51,0 16 1,1 C37 Timus / Thymus 10 7 - 3 - 0 - 0 - C38 Srce, mediastinum, plevra / Heart, mediastinum, pleura Druga in slabo opredeljena mesta v dihalih in prsnih organih 5 0 - 1 - 2 - 2 - C39 Other and ill-defined sites in the respiratory system and intrathoracic organs 0 0 - 0 - 0 - 0 - C40 Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs 9 3 - 2 - 4 - 0 - C41 Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts 12 1 - 7 - 4 - 0 - C43 Maligni melanom kože / Malignant melanoma of skin 578 437 75,6 132 22,8 8 1,4 1 0,2 C44 Druge maligne neoplazme kože / Skin, other malignomas 3156 3131 99,2 20 0,6 1 0,0 4 0,1 C45 Mezoteliom / Mesothelioma 43 10 23,3 25 58,1 5 11,6 3 7,0 C46 Kaposijev sarkom / Kaposi’s sarcoma 0 0 - 0 - 0 - 0 - C47 Periferni živci in avtonomno živcevje Peripheral nerves and autonomic nervous system 3 1 - 1 - 1 - 0 - C48 Peritonej in retroperitonej / Retroperitoneum and peritoneum 24 1 4,2 8 33,3 15 62,5 0 0,0 C49 Drugo vezivno in mehko tkivo / Other connective and soft tissue 47 22 46,8 19 40,4 4 8,5 2 4,3 C50 Dojka / Breast 1409 809 57,4 478 33,9 111 7,9 11 0,8 Nadaljevanje —> Continued —> 44 Tabela 5: Nadaljevanje. Table 5: Continued. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage Omejen Localized Razširjen Regional Razsejan Distant Neznan Unknown ** Število Number %* Število Number %* Število Number %* Število Number %* C51 Žensko zunanje spolovilo / Vulva 58 26 44,8 29 50,0 3 5,2 0 0,0 C52 Nožnica / Vagina 12 6 - 5 - 0 - 1 - C53 Maternicni vrat / Cervix uteri 86 39 45,3 38 44,2 8 9,3 1 1,2 C54 Maternicno telo / Corpus uteri 351 244 69,5 70 19,9 27 7,7 10 2,8 C55 Maternica, neopredeljeno / Uterus, unspecified 20 9 45,0 5 25,0 4 20,0 2 10,0 C56 Jajcnik / Ovary 157 19 12,1 14 8,9 123 78,3 1 0,6 C57 Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs 25 1 4,0 2 8,0 22 88,0 0 0,0 C58 Posteljica / Placenta 1 0 - 0 - 1 - 0 - C60 Penis / Penis 12 9 - 2 - 1 - 0 - C61 Prostata / Prostate 1595 1049 65,8 359 22,5 132 8,3 55 3,4 C62 Modo / Testis 125 96 76,8 18 14,4 11 8,8 0 0,0 C63 Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs 3 2 - 0 - 1 - 0 - C64 Ledvica razen meha / Kidney, except renal pelvis 365 218 59,7 54 14,8 86 23,6 7 1,9 C65 Ledvicni meh / Renal pelvis 38 11 28,9 11 28,9 16 42,1 0 0,0 C66 Secevod / Ureter 15 5 33,3 7 46,7 2 13,3 1 6,7 C67 Secni mehur / Bladder 357 264 73,9 58 16,2 27 7,6 8 2,2 C68 Drugi in neopredeljeni secni organi Other and unspecified urinary organs 1 1 - 0 - 0 - 0 - C69 Oko in ocesni adneksi / Eye and adnexa 20 18 90,0 2 10,0 0 0,0 0 0,0 C70 Meninge / Meninges 3 2 - 0 - 1 - 0 - C71 Možgani / Brain 195 195 100,0 0 0,0 0 0,0 0 0,0 C72 Hrbtni mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS 3 2 - 1 - 0 - 0 - C73 Šcitnica / Thyroid gland 211 154 73,0 49 23,2 8 3,8 0 0,0 C74 Nadledvicna žleza / Adrenal gland 13 8 - 2 - 2 - 1 - C75 Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures 4 1 - 2 - 1 - 0 - C76 Druga in slabo opredeljena mesta / Other and ill-defined sites 11 1 - 4 - 6 - 0 - C77 Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes 30 0 0,0 0 0,0 1 3,3 29 96,7 C78 Metastaze dihal in prebavil Metastases of respiratory and digestive organs 65 0 0,0 0 0,0 65 100,0 0 0,0 C79 Metastaze, drugje / Metastases of other sites 17 0 0,0 0 0,0 17 100,0 0 0,0 C80 Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site 111 0 0,0 0 0,0 111 100,0 0 0,0 Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Stadij / Stage I II III + IV Neznan / Unknown Število Number %* Število Number %* Število Number %* Število Number %* C81 Hodgkinov limfom / Hodgkin’s lymphoma 57 7 12,3 20 35,1 30 52,6 0 0,0 C82 Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin’s lymphoma 109 30 27,5 9 8,3 65 59,6 5 4,6 C83 Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin’s lymphoma 235 40 17,0 23 9,8 152 64,7 20 8,5 C84 Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas 26 9 34,6 2 7,7 14 53,8 1 3,8 C85 Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin’s lymphoma 20 5 25,0 2 10,0 8 40,0 5 25,0 * Odstotki niso racunani, ce je število novih primerov manjše od 15 Percentages are not calculated when number of new cases is less than 15 ** Vkljuceni tudi primeri, ki so registrirani samo iz zdravniških porocil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage Prevalenca Prevalence Tabela 6: Prevalenca po spolu, Slovenija, 31. 12. 2017. Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2017. Šifra MKB ICD code Primarna lokacija* Primary site* Spol Sex Leta po diagnozi Years after diagnosis Celotnaprevalenca Lifetime prevalence <1 1-4 5-9 10+ Vsi / All C00-C96 Vse lokacije All sites M+Ž M Ž 12286 6404 5882 35267 18146 17121 30248 15081 15167 41417 15417 26000 111696 50941 60755 C00-C14 Usta in žrelo Mouth and pharynx M Ž 229 76 550 226 445 166 491 277 1715 745 C15 Požiralnik Oesophagus M Ž 38 12 40 13 16 6 24 11 118 42 C16 Želodec Stomach M Ž 163 110 362 220 260 186 400 355 1185 871 C18 Debelo crevo Colon M Ž 375 276 1130 870 1173 909 1010 1095 3688 3150 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 284 168 904 491 910 555 889 787 2987 2001 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 89 35 96 33 26 8 20 12 231 88 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 44 49 64 68 34 34 33 40 175 191 C25 Trebušna slinavka Pancreas M Ž 108 99 73 79 29 30 22 29 232 237 C32 Grlo Larynx M Ž 83 6 217 33 226 30 342 57 868 126 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 515 389 765 578 354 234 398 201 2032 1402 C43 Maligni melanom kože Malignant melanoma of skin M Ž 291 271 996 906 798 961 925 1534 3010 3672 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 1519 1584 4861 4862 3785 4103 4091 5131 14256 15680 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 24 36 73 104 64 70 203 211 364 421 C50 Dojka Breast M Ž 10 1348 38 4611 34 4299 33 7610 115 17868 C53 Maternicni vrat Cervix uteri M Ž - 78 - 343 - 419 - 2651 - 3491 C54 Maternicno telo Corpus uteri M Ž - 325 - 1109 - 1025 - 2325 - 4784 C56 JajcnikOvary M Ž - 127 - 313 - 273 - 880 - 1593 C61 Prostata Prostate M Ž 1510 - 5383 - 4757 - 2491 - 14141 - C62 Modo Testis M Ž 125 - 449 - 493 - 1463 - 2530 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 227 89 617 357 584 284 659 480 2087 1210 C67 Secni mehur Bladder M Ž 217 80 539 189 384 107 431 152 1571 528 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 79 55 110 75 71 58 198 158 458 346 C73 Šcitnica Thyroid gland M Ž 46 161 143 539 151 527 243 1040 583 2267 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 29 24 89 91 90 102 360 330 568 547 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma M Ž 141 165 558 495 402 418 539 568 1640 1646 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 67 49 149 130 84 75 53 48 353 302 C91-C95 Levkemije Leukaemias M Ž 144 98 366 292 268 221 410 355 1188 966 * Pri posameznih lokacijah je pri prikazu prevalence oseba z vec raki vkljucena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z vec raki šteje le enkrat For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only Umrljivost Mortality Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2017. Vir: Nacionalni inštitut za javno zdravje Table 7: Cancer mortality by age and by sex, Slovenia 2017. Source: National Institute of Public Health Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Vse starosti All ages Starost / Age 0-19 20-49 50-74 75+ C00-C97 Vse lokacije All sites M+Ž M Ž 6365 3570 2795 12 6 6 205 96 109 2982 1815 1167 3166 1653 1513 C00-C14 Usta in žrelo Mouth and pharynx M Ž 120 24 0 0 6 2 93 13 21 9 C15 Požiralnik Oesophagus M Ž 73 21 0 0 8 0 51 11 14 10 C16 Želodec Stomach M Ž 201 129 0 1 2 4 99 43 100 81 C18 Debelo crevo Colon M Ž 252 176 0 0 8 6 104 49 140 121 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 164 111 0 0 4 3 77 39 83 69 C22 Jetra in intrahepaticni vodi Liver and intrahepatic bile ducts M Ž 198 85 0 0 3 1 131 42 64 42 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 46 71 0 0 0 0 20 24 26 47 C25 Trebušna slinavka Pancreas M Ž 190 194 0 0 4 2 103 84 83 108 C32 Grlo Larynx M Ž 59 5 0 0 2 0 40 4 17 1 C33-C34 Sapnik, sapnici in pljuca Trachea, bronchus and lung M Ž 787 458 0 0 10 8 528 281 249 169 C43 Maligni melanom kože Malignant melanoma of skin M Ž 59 52 0 0 4 5 34 17 21 30 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž 20 30 0 0 0 0 6 1 14 29 C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 20 33 0 0 4 4 10 12 6 17 C50 Dojka Breast M Ž 2 433 0 0 0 27 2 173 0 233 C53 Maternicni vrat Cervix uteri M Ž - 43 - 0 - 13 - 16 - 14 C54 Maternicno telo Corpus uteri M Ž - 65 - 0 - 2 - 28 - 35 C56 Jajcnik Ovary M Ž - 136 - 0 - 6 - 83 - 47 C61 Prostata Prostate M Ž 464 - 0 - 1 - 124 - 339 - C62 Modo Testis M Ž 5 - 0 - 1 - 2 - 2 - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 125 60 0 0 4 2 57 21 64 37 C67 Secni mehur Bladder M Ž 143 77 0 0 0 1 52 25 91 51 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 108 69 2 3 17 8 61 33 28 25 C73 Šcitnica Thyroid gland M Ž 6 6 0 0 1 0 2 3 3 3 C81 Hodgkinov limfom Hodgkin’s lymphoma M Ž 2 3 0 0 0 0 1 1 1 2 C82-C85 Ne-Hodgkinovi limfomi Non-Hodgkin’s lymphoma M Ž 74 83 0 0 3 0 30 36 41 47 C90 Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms M Ž 68 51 0 0 0 1 30 16 38 34 C91-C95 Levkemije Leukaemias M Ž 127 96 1 2 7 1 53 32 66 61 Preživetje Survival Tabela 8: Eno- in pet-letno cisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2013–2017. Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2013–2017 by sex. Šifra MKB ICD code Primarna lokacija Primary site Spol Sex Eno-letno preživetje s 95 % intervalom zaupanja Pet-letno preživetje s 95 % intervalom zaupanja One-year survival with 95% confidence interval Five-year survival with 95% confidence interval C00-C96 brez C44** Vse lokacije All sites M+Ž M Ž 74,0 73,6-74,4 72,4 71,9-73,0 75,9 75,3-76,4 58,4 57,8-58,9 56,7 56,0-57,4 60,4 59,6-61,2 C00-C14 Usta in žrelo Mouth and pharynx M Ž 72,1 69,6-74,6 84,7 81,0-88,6 44,0 40,9-47,2 66,1 59,9-73,0 C15 Požiralnik Oesophagus M Ž 39,1 34,2-44,8 38,7 29,5-51,0 10,0 6,9-14,4 17,2 10,5-28,2 C16 Želodec Stomach M Ž 52,0 49,3-54,8 49,0 45,6-52,7 30,3 27,5-33,5 30,5 26,9-34,5 C18 Debelo crevo Colon M Ž 78,9 77,1-80,8 76,2 74,1-78,3 61,5 58,7-64,5 62,1 59,1-65,2 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction M Ž 84,4 82,6-86,3 79,1 76,4-81,9 64,3 61,2-67,5 59,2 55,2-63,4 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts M Ž 33,0 29,8-36,6 32,3 27,3-38,3 10,7 8,4-13,7 10,7 7,4-15,5 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract M Ž 35,9 31,5-40,9 31,1 27,3-35,5 14,1 10,8-18,5 14,5 11,3-18,5 C25 Trebušna slinavka Pancreas M Ž 24,8 22,2-27,8 24,9 22,2-27,9 6,0 4,4-8,1 6,9 5,3-9,1 C32 Grlo Larynx M Ž 85,9 82,3-89,5 * 60,3 54,4-66,8 * C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung M Ž 41,8 40,3-43,3 50,5 48,5-52,5 16,0 14,7-17,3 23,4 21,5-25,5 C43 Maligni melanom kože Malignant melanoma of skin M Ž 97,6 96,4-98,8 98,0 96,9-99,1 91,6 88,7-94,6 91,4 88,6-94,4 C44 Druge maligne neoplazme kože Skin, other malignomas M Ž ** ** ** ** C48-C49 Vezivno in mehko tkivo Connective and soft tissue M Ž 79,1 72,6-86,3 79,7 74,3-85,6 56,7 47,8-67,2 53,0 45,8-61,5 C50 Dojka Breast M Ž * 96,8 96,3-97,4 * 88,0 86,6-89,3 C53 Maternicni vrat Cervix uteri M Ž - - 85,8 82,8-88,9 - - 67,8 63,2-72,7 C54 Maternicno telo Corpus uteri M Ž - - 91,5 90,0-93,0 - - 80,3 77,7-83,0 C56 JajcnikOvary M Ž - - 74,6 71,5-77,8 - - 40,0 36,3-44,2 C61 Prostata Prostate M Ž 97,3 96,8-97,8 - - 93,3 92,0-94,6 - - C62 Modo Testis M Ž 99,1 98,3-99,9 - - 97,3 95,6-99,0 - - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis M Ž 78,3 75,9-80,8 77,0 73,7-80,5 65,7 62,1-69,4 67,3 62,7-72,2 C67 Secni mehur Bladder M Ž 74,0 71,4-76,7 70,4 66,1-74,9 53,9 49,9-58,3 49,1 43,1-56,0 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system M Ž 47,8 43,7-52,4 45,7 40,8-51,2 20,5 17,1-24,6 19,6 15,7-24,4 C73 Šcitnica Thyroid gland M Ž 95,1 91,9-98,4 96,9 95,5-98,3 90,8 85,4-96,5 95,8 93,4-98,3 C81 Hodgkinov limfomHodgkin’s lymphoma M Ž 90,8 86,0-96,0 92,8 88,1-97,7 83,5 76,5-91,1 88,4 81,2-96,3 C82-C85 Ne-Hodgkinovi limfomiNon-Hodgkin’s lymphoma M Ž 75,8 73,1-78,6 76,9 74,2-79,7 65,7 61,9-69,8 62,1 58,3-66,1 C90 Difuzni plazmocitom in maligne neoplazme plazmatkMultiple myeloma and malignant plasma cell neoplasms M Ž 72,3 67,6-77,4 75,4 70,4-80,7 42,3 35,7-50,1 44,6 37,7-52,8 C91-C95 Levkemije Leukaemias M Ž 67,8 64,7-71,1 68,4 64,9-72,2 51,8 47,7-56,1 49,8 44,8-55,3 * Število v analizo vkljucenih bolnikov je manjše od 15 povprecno letno / Average number of patients included in the analysis is less than 15 yearly** Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population Zdravljenje Treatment Tabela 9a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL). Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in2017, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (inparenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given). Šifra MKB ICD code Primarna lokacija Primary site Število novih primerov Number of new cases Število kakorkoli zdravljenih* Number of all treated* Število operiranih Number of treated by surgery Število zdravljenih s sistemsko terapijo Number of treated systemic therapy Število obsevanih Number of treated by radiotherapy Število Number %** Število Number %** Število Number %** Število (od tega OIL) Number (IOL only) %** C00-C96 Vse lokacije / All sites 14946 12128 81,1 9487 63,5 4294 28,7 3180 (2937) 21,3 C00-C14 Usta in žrelo Mouth and pharynx 350 325 92,9 186 53,1 25 7,1 257 (256) 73,4 C15 Požiralnik Oesophagus 88 49 55,7 16 18,2 31 35,2 38 (37) 43,2 C16 Želodec Stomach 423 263 62,2 193 45,6 127 30,0 68 (67) 16,1 C18 Debelo crevo Colon 782 671 85,8 643 82,2 188 24,0 10 (10) - C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 536 445 83,0 378 70,5 197 36,8 213 (211) 39,7 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 260 101 38,8 41 15,8 56 21,5 1 (0) - C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 194 88 45,4 66 34,0 28 14,4 5 (3) - C25 Trebušna slinavka Pancreas 406 167 41,1 91 22,4 108 26,6 10 (9) - C32 Grlo Larynx 94 89 94,7 44 46,8 6 - 69 (68) 73,4 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1451 1022 70,4 332 22,9 524 36,1 556 (512) 38,3 C43 Maligni melanom kože Malignant melanoma of skin 578 575 99,5 574 99,3 12 - 32 (32) 5,5 C44 Druge maligne neoplazme kože Skin, other malignomas 3156 3098 98,2 2990 94,7 23 0,7 105 (105) 3,3 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 71 62 87,3 52 73,2 21 29,6 20 (19) 28,2 C50 Dojka Breast 1403 1358 96,8 1202 85,7 1217 86,7 860 (692) 61,3 C53 Maternicni vrat Cervix uteri 86 79 91,9 57 66,3 3 - 46 (45) 53,5 C54 Maternicno telo Corpus uteri 350 330 94,3 311 88,9 52 14,9 122 (122) 34,9 C56 JajcnikOvary 157 127 80,9 111 70,7 101 64,3 4 (3) - C61 Prostata Prostate 1590 1105 69,5 760 47,8 438 27,5 202 (199) 12,7 C62 Modo Testis 125 125 100 125 100,0 69 55,2 1 (1) - C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 402 321 79,9 295 73,4 32 8,0 19 (16) 4,7 C67 Secni mehur Bladder 356 328 92,1 324 91,0 47 13,2 20 (19) 5,6 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 201 164 81,6 160 79,6 96 47,8 113 (110) 56,2 C73 Šcitnica Thyroid gland 211 207 98,1 199 94,3 202 95,7 125 (125) 59,2 C81 Hodgkinov limfomHodgkin’s lymphoma 57 52 91,2 0 - 50 87,7 29 (29) 50,9 C82-C85 ne-Hodgkinovi limfominon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 390 276 70,8 51 13,1 211 54,1 94 (94) 24,1 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 141 119 84,4 5 - 112 79,4 18 (16) 12,8 C91-C95 Levkemije Leukaemias 329 171 52,0 2 - 167 50,8 14 (14) - * Število kakorkoli zdravljenih v okviru prvega zdravljenja, ne glede na nacin zdravljenja (vkljucno z drugimi zdravljenji, ki ne spadajo pod operacijo, sistemsko terapijo ali obsevanje) Number of all treated patients regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy) ** Odstotki niso racunani, ce je število zdravljenih manjše od 15 Percentages are not calculated for less than 15 cases Tabela 9b: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji bolelih leta 2017, ki so bili v okviru prvega zdravljenja operirani*, po bolnici posega. Table 9b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by surgery during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerovNumber of new casesŠtevilo operiranihNumber of treated by surgerySplošna bolnišnica CeljeSplošna bolnišnica JeseniceSplošna bolnišnica IzolaUniverzitetni klinicni centerLjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni centerMariborSplošna bolnišnica Murska SobotaSplošna bolnišnica NovaGoricaSplošna bolnišnica NovomestoSplošna bolnišnicaPtujSplošna bolnišnica SlovenjGradecSplošna bolnišnica TrbovljeZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacijeAll sites 14946 9487 773 298 202 2403 1361 1592 349 345 482 89 553 33 862 145 C00-C14 Usta in žrelo Mouth and pharynx 350 186 3 1 0 103 0 70 3 2 3 0 0 0 0 1 C15 Požiralnik Oesophagus 88 16 0 0 0 14 0 1 0 0 0 0 0 0 1 0 C16 Želodec Stomach 423 193 9 5 4 95 11 51 8 1 0 0 4 0 4 1 C18 Debelo crevo Colon 782 643 52 53 26 182 44 87 31 26 36 20 35 17 29 5 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 536 378 21 20 23 93 70 47 22 3 20 9 19 6 23 2 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 260 41 0 0 0 22 0 19 0 0 0 0 0 0 0 0 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 194 66 1 0 1 35 0 21 1 3 2 0 2 0 0 0 C25 Trebušna slinavka Pancreas 406 91 0 0 1 60 0 28 0 0 0 0 0 0 0 2 C32 Grlo Larynx 94 44 0 0 0 33 0 11 0 0 0 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1451 332 1 0 0 112 0 65 0 0 0 0 0 0 145 9 C43 Maligni melanom kože Malignant melanoma of skin 578 574 63 28 18 133 33 82 13 21 35 2 22 2 80 42 C44 Druge maligne neoplazme kože Skin, other malignomas 3156 2990 363 166 40 520 36 572 185 113 251 56 129 1 544 14 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 71 52 2 1 1 8 27 1 4 2 2 1 1 0 2 0 C50 Dojka Breast 1403 1202 25 0 36 0 887 150 2 68 0 0 31 0 1 2 C53 Maternicni vrat Cervix uteri 86 57 2 3 1 33 5 4 1 0 1 0 1 0 0 6 C54 Maternicno telo Corpus uteri 350 311 18 9 7 134 33 50 17 6 3 0 16 4 0 14 C56 JajcnikOvary 157 111 8 3 2 44 22 20 2 1 1 0 4 0 0 4 C61 Prostata Prostate 1590 760 140 0 16 135 0 90 33 55 42 0 221 0 18 10 C62 Modo Testis 125 125 8 0 5 69 0 16 2 5 9 0 5 0 0 6 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 402 295 17 0 5 112 1 52 10 17 38 0 35 0 1 7 C67 Secni mehur Bladder 356 324 18 0 11 147 0 55 10 18 31 0 25 0 0 9 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 201 160 2 0 0 117 0 36 0 0 0 0 0 0 0 5 C73 Šcitnica Thyroid gland 211 199 11 0 0 26 145 10 0 0 0 0 0 0 7 0 C81 Hodgkinov limfomHodgkin’s lymphoma 57 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 C82-C85 ne-Hodgkinovi limfominon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne390 51 1 2 0 19 8 10 3 1 4 0 0 1 2 0 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 141 5 0 0 0 1 0 4 0 0 0 0 0 0 0 0 C91-C95 Levkemije Leukaemias 329 2 0 0 0 1 0 1 0 0 0 0 0 0 0 0 * Bolniki, ki so bili v okviru prvega zdravljenja operirani vec kot enkrat, so vkljuceni le s prvo operacijo Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only ** V posamezni ustanovi so operirali manj kot 30 bolnikov Less then 30 patients were treated by surgery in individual institution Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških porocil o vzroku smrti), v Sloveniji zbolelih leta 2017, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po bolnici zdravljenja. Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2017, that were treated by systemic therapy during their first treatment* by treatment institution. Šifra MKB ICD code Primarna lokacija Primary site Število novih primerovNumber of new casesŠtevilo zdravljenih s sistemsko terapijoNumber of treatedsystemic therapySplošna bolnišnica CeljeBolnišnica GolnikSplošna bolnišnica IzolaUniverzitetni klinicni centerLjubljanaOnkološki inštitut LjubljanaUniverzitetni klinicni centerMariborSplošna bolnišnica Murska SobotaSplošna bolnišnica Nova GoricaSplošna bolnišnica Novo mestoSplošna bolnišnica SlovenjGradecZasebne ordinacijePrivate clinicsOstale ustanove** Other institutions** C00-C96 Vse lokacijeAll sites 14946 4294 122 145 28 440 2567 712 34 96 24 84 22 20 C00-C14 Usta in žrelo Mouth and pharynx 350 25 0 1 0 0 24 0 0 0 0 0 0 0 C15 Požiralnik Oesophagus 88 31 0 0 0 1 26 3 0 0 0 0 0 1 C16 Želodec Stomach 423 127 3 0 0 14 73 33 0 4 0 0 0 0 C18 Debelo crevo Colon 782 188 11 0 0 9 110 45 0 4 0 9 0 0 C19-C20 Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction 536 197 2 0 0 2 177 15 0 0 0 1 0 0 C22 Jetra in intrahepaticni vodiLiver and intrahepatic bile ducts 260 56 1 0 0 38 2 12 0 0 0 1 0 2 C23-C24 Žolcnik in žolcevodi Gallbladder and billiary tract 194 28 0 0 0 13 3 12 0 0 0 0 0 0 C25 Trebušna slinavka Pancreas 406 108 3 0 0 42 29 27 0 4 0 3 0 0 C32 Grlo Larynx 94 6 0 0 0 0 6 0 0 0 0 0 0 0 C33-C34 Sapnik, sapnici in pljucaTrachea, bronchus and lung 1451 524 0 138 0 0 264 120 0 0 0 0 0 2 C43 Maligni melanom kože Malignant melanoma of skin 578 12 0 0 0 0 12 0 0 0 0 0 0 0 C44 Druge maligne neoplazme kože Skin, other malignomas 3156 23 1 0 0 4 2 14 0 0 0 0 0 2 C48-C49 Vezivno in mehko tkivo Connective and soft tissue 71 21 0 0 0 1 18 2 0 0 0 0 0 0 C50 Dojka Breast 1403 1217 41 0 19 0 850 237 0 43 0 23 1 3 C53 Maternicni vrat Cervix uteri 86 3 0 0 0 0 3 0 0 0 0 0 0 0 C54 Maternicno telo Corpus uteri 350 52 0 0 0 2 41 8 0 1 0 0 0 0 C56 JajcnikOvary 157 101 0 0 0 0 79 22 0 0 0 0 0 0 C61 Prostata Prostate 1590 438 30 0 9 51 164 71 13 32 14 36 15 3 C62 Modo Testis 125 69 0 0 0 1 68 0 0 0 0 0 0 0 C64-C65 Ledvica z ledvicnim mehom Kidney with renal pelvis 402 32 0 0 0 1 24 6 0 1 0 0 0 0 C67 Secni mehur Bladder 356 47 0 0 0 1 34 6 3 2 0 1 0 0 C70-C72 Centralni in avtonomni živcni sistem Central and autonomic nervous system 201 96 0 0 0 4 92 0 0 0 0 0 0 0 C73 Šcitnica Thyroid gland 211 202 11 0 0 25 150 10 0 0 0 0 6 0 C81 Hodgkinov limfomHodgkin’s lymphoma 57 50 0 0 0 6 44 0 0 0 0 0 0 0 C82-C85 ne-Hodgkinovi limfominon-Hodgkin’s lymphoma Difuzni plazmocitom in maligne 390 211 2 1 0 18 180 6 1 1 0 2 0 0 C90 neoplazme plazmatkMultiple myeloma and malignantplasma cell neoplasms 141 112 12 0 0 60 0 12 9 2 9 5 0 3 C91-C95 Levkemije Leukaemias 329 167 4 0 0 115 6 26 7 2 1 3 0 3 * Bolniki, ki so v okviru prvega zdravljenja prejeli vec kot eno vrsto sistemskega zdravljenja, so vkljuceni le enkrat Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only ** V posamezni ustanovi so zdravili manj kot 10 bolnikov Less then 10 patients were treated in indivdual institution Breme najpogostejših rakov Cancer Fact Sheets Vsi raki / All cancer sites (C00–C96) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Število novih primerov v enem letu / Number of new cases per year Moški / Men 7928 Ženske / Women 6708 Skupaj / All 14636 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 100,0 100,0 100,0 Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 121,9 126,6 124,1 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 38,1 28,6 33,2 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 775,2 644,9 709,5 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 401,9 300,6 343,4 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,88* 2,08* 1,98* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year -0,21 3456 0,98* 2704 0,43 6160 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 100 100 100 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 15,8 9,5 12,6 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 337,9 260 298,6 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 157,6 92,1 120,1 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 1,01* 0,78* 0,92* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) -1,76* 57766 -0,74* 66521 -1,25* 124287 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 5630,4 6395,1 6015,4 1-letna prevalenca / 1-year prevalence 6605 5992 12597 5-letna prevalenca / 5-year prevalence 25742 23732 49474 * Statisticno znacilno / Statistically significant 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 600 500 400 300 200 100 900 800 700 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 400 350 300 250 200 Umrljivost 150 Mortality100 Slovenija 50 1985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Leto / Year Prostata / Prostate (C61) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Število novih primerov v enem letu / Number of new cases per year 1613 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 20,3 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 1. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 24,8 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 10,3 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 157,7 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 78,6 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 1,97* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,23 UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 403 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 11,7 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,1 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 39,4 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 15,3 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 2,09* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,61* PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 14143 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 1378,5 1-letna prevalenca / 1-year prevalence 1510 5-letna prevalenca / 5-year prevalence 6893 * Statisticno znacilno / Statistically significant Incidenca 180 Incidence 160 Slovenija 140 1961–2017 120 100 80 60 40 20 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Leto / Year Groba stopnja MOŠKIStarostno standardizirana stopnja MOŠKI Crude rate MALE Age-standardized rate MALE 15 Mortality10 Slovenija 51985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Umrljivost Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 45 40 35 Pljuca in sapnik / Lung and trachea (C33, C34) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 927 495 1422 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 11,7 7,4 9,7 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 3. 4. 3. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 14,3 9,3 12,1 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 5,7 2,7 4,1 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 90,6 47,6 68,9 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 46,0 21,7 32,8 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 0,75 5,94* 2,41* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -1,44* 4,83* 0,68 UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 798 389 1187 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 23,1 14,4 19,3 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 4,7 1,9 3,2 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 78,0 37,4 57,5 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 38,4 15,6 25,9 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 0,14 4,15* 1,40* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,14* 2,87* -0,41 PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 2033 1402 3435 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 198,2 134,8 166,3 1-letna prevalenca / 1-year prevalence 515 389 904 5-letna prevalenca / 5-year prevalence 1281 967 2248 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 120 100 80 60 40 20 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 60 50 40 30 20 10 80 70 90 1985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Dojka / Breast (C50) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Ženske / Women Število novih primerov v enem letu / Number of new cases per year 1345 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 20,0 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 25,4 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 7,6 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 129,3 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 70,0 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,00* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,32* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 408 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 15,1 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,6 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 39,2 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 14,5 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -0,71 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,38* PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 17869 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 1717,9 1-letna prevalenca / 1-year prevalence 1348 5-letna prevalenca / 5-year prevalence 5959 * Statisticno znacilno / Statistically significant Incidenca 160 Incidence 140 Slovenija 1201961–2017 100 80 60 40 20 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Leto / Year Groba stopnja ŽENSKEStarostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 45 40 35 30 25 20 Umrljivost 15 Mortality10 Slovenija 5 1985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Groba in starostno standardizirana stopnja na 100.000Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Crude and age-standardized rate per 100.00 Debelo crevo in danka / Colon and rectum (C18–C20) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 825 567 1393 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 10,4 8,5 9,5 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 4. 3. 4. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 12,7 10,7 11,8 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 4,7 2,5 3,6 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 80,7 54,5 67,5 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 40,3 21,6 30,1 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -1,98* -2,26* -2,09* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -4,23* -3,85* -3,94* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 439 321 760 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 12,7 11,9 12,3 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 2,04 0,94 1,46 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 42,9 30,9 36,8 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 19,5 9,6 13,9 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -0,31 -1,26 -0,74 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,04* -3,26* -3,02* PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 6676 5151 11827 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 650,7 495,2 572,4 1-letna prevalenca / 1-year prevalence 659 444 1103 5-letna prevalenca / 5-year prevalence 2694 1805 4499 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 120 100 80 60 40 20 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 15 10 5 45 40 35 50 1985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Koža, razen melanoma / Skin, non-melanoma (C44) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 1427 1411 2838 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 18,0 21,0 19,4 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 2. 1. 1. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 21,9 26,6 24,1 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 7,3 5,8 6,5 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 139,5 135,7 137,6 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 67,7 54,3 59,5 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 5,27* 4,32* 4,79* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,81* 3,35* 3,15* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 15 19 34 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 0,4 0,7 0,6 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,04 0,01 0,02 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 1,5 1,8 1,7 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 0,6 0,3 0,4 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 1,37 0,91 0,84 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,07 -2,90 -4,06 PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 14257 15681 29938 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 1389,6 1507,5 1449,0 1-letna prevalenca / 1-year prevalence 1519 1584 3103 5-letna prevalenca / 5-year prevalence 6381 6447 12828 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 120 100 80 60 40 20 0 180 160 140 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE 20 18 16 14 12 10 8 Umrljivost 6 Mortality4 Slovenija 2 1985–2017 0 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Kožni melanom / Malignant melanoma of skin (C43) INCIDENCA (povprecje v obdobju 2013-2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 295 261 556 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 3,7 3,9 3,8 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 6. 6. 6. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 4,5 4,9 4,7 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 1,8 1,5 1,6 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 28,9 25,1 26,9 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 16,6 14,5 15,3 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 3,90* 0,97 2,46* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,93* -0,31 0,75 UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 67 54 122 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,0 2,0 2,0 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,4 0,2 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 6,6 5,2 5,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 3,3 2,1 2,7 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 2,15 -0,35 0,93 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -0,76 -2,48 -1,57 PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 3013 3675 6688 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 293,7 353,3 323,7 1-letna prevalenca / 1-year prevalence 291 271 562 5-letna prevalenca / 5-year prevalence 1290 1180 2470 * Statisticno znacilno / Statistically significant Incidenca 35 Incidence Slovenija 30 1961–2017 25 20 15 10 5 0 Leto / Year Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija1985–2017 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 15 10 5 45 40 35 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Glava in vrat / Head and neck (C00–C14, C30–C32) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 371 99 470 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 4,7 1,5 3,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. 14. 7. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 5,7 1,9 4,0 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 2,5 0,6 1,5 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 36,3 9,5 22,8 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 20,3 4,9 12,4 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) -0,72 2,45 -0.08 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -2,47* 1,58 -1,60* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013-2017) Število smrti v enem letu / Number of deaths per year 180 36 216 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 5,2 1,3 3,5 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 1,2 0,2 0,7 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 17,6 3,5 10,5 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 9,4 1,5 5,2 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) -1,52* 0,78 -1,10 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) -3,48* 0,05 -2,87* PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 2662 928 3590 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 259,5 89,2 173,8 1-letna prevalenca / 1-year prevalence 322 88 410 5-letna prevalenca / 5-year prevalence 1107 358 1465 * Statisticno znacilno / Statistically significant 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 30 25 20 15 10 5 45 40 35 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija1985–2017 30 25 20 15 10 5Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Maternicno telo / Corpus uteri (C54) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Ženske / Women Število novih primerov v enem letu / Number of new cases per year 347 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 5,2 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 5. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 6,5 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 2,0 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 33,3 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 15,8 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 2,81* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,52* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 61 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,3 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,2 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 5,9 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 2,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 3,17 Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,01 PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 4784 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 459,9 1-letna prevalenca / 1-year prevalence 325 5-letna prevalenca / 5-year prevalence 1434 * Statisticno znacilno / Statistically significant Leto / Year Groba stopnja ŽENSKEStarostno standardizirana stopnja ŽENSKE Crude rate FEMALE Age-standardized rate FEMALE 45 40 35 30 25 20 Umrljivost 15 Mortality10 Slovenija 51985–2017 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 40 30 20 15 10 5 0 35 25 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Groba in starostno standardizirana stopnja na 100.000 Crude and age-standardized rate per 100.00 Ne-Hodgkinov limfom / Non-Hodgkin’s lymphoma (C82–C85) INCIDENCA (povprecje v obdobju 2013–2017) / INCIDENCE (average 2013–2017) Moški / Men Ženske / Women Skupaj / All Število novih primerov v enem letu / Number of new cases per year 215 202 417 Odstotek med vsemi raki (%) / Percentage of all cancers (%) 2,7 3,0 2,8 Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers 10. 7. 9. Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers except non-melanoma skin (%) 3,3 3,8 3,5 Tveganje raka do 75. leta starosti (KT) (%) / Risk of getting cancer before age 75 (CR) (%) 1,2 1,0 1,1 Groba incidencna stopnja na 100.000 / Crude incidence rate per 100,000 21,0 19,5 20,2 Starostno standardizirana incidencna stopnja (SSS) na 100.000 (W) / Age-standardized incidence rate (ASR) per 100,000 (W) 11,5 8,7 10,0 Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%) 5,29* 4,57* 4,93* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 2,92* 3,57* 3,23* UMRLJIVOST (povprecje v obdobju 2013–2017) / MORTALITY (average 2013–2017) Število smrti v enem letu / Number of deaths per year 83 86 169 Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%) 2,4 3,2 2,7 Tveganje smrti za rakom do 75. leta starosti (KT) (%) / Risk of dying from cancer before age 75 (CR) (%) 0,4 0,2 0,3 Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000 8,1 8,2 8,2 Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 (W) / Age-standardized mortality rate (ASR) per 100,000 (W) 3,8 2,4 3,0 Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%) 4,82* 5,47* 5,11* Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%) 1,75 3,72 2,71 PREVALENCA (na dan 31.12.2017) / PREVALENCE (on December 31, 2017) Število živih oseb z diagnozo raka ob koncu leta 2017 (prevalenca) / Persons living with cancer at the end of 2017 (prevalence) 1641 1648 3289 Število živih oseb z diagnozo raka na 100.000 (prevalencna stopnja) / Number of persons living with cancer per 100,000 at the end of 2017 159,9 158,4 159,2 1-letna prevalenca / 1-year prevalence 141 165 306 5-letna prevalenca / 5-year prevalence 699 660 1359 * Statisticno znacilno / Statistically significant Leto / Year Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 Incidenca Incidence Slovenija1961–2017 30 25 20 15 10 5 0 1961 1965 1969 1973 1977 1981 1985 1989 1993 1997 2001 2005 2009 2013 2017 Groba stopnja MOŠKIGroba stopnja ŽENSKEStarostno standardizirana stopnja MOŠKIStarostno standardizirana stopnja ŽENSKE Crude rate MALE Crude rate FEMALE Age-standardized rate MALE Age-standardized rate FEMALE UmrljivostMortalitySlovenija1985–2017 Groba in starostno standardizirana stopnja na 100.000Crude and age-standardized rate per 100.00 30 25 20 15 10 5 45 40 35 0 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017 Leto / Year Pojmovnik62Incidenca Umrljivost Prevalenca PreživetjeGroba stopnja Starostno standardizirana stopnja Kumulativna stopnja Kumulativno tveganje Ocena incidence PojmovnikDefinicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA: http://www.slora.si/definicije-kazalnikov-in-metod. Število vseh na novo ugotovljenih primerov raka v tocno doloceni populaciji v enem koledarskem letu. Število vseh umrlih za doloceno boleznijo v tocno doloceni populaciji v enem koledarskem letu. Število vseh bolnikov z doloceno boleznijo, ki so bili živi na izbrani datum (po- navadi zadnji dan v letu). Glede na cas, kdaj so zboleli, locimo: .Celotna prevalenca upošteva vse bolnike z rakom, ne glede na to kdaj so zboleli. .Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v tocno dolocenem obdobju pred datumom izracuna. Na primer, v enoletni delni prevalenci so vkljuceni bolniki, ki so zboleli leto pred datumom izracuna ter so na ta datum še živi. Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V porocilu podajamo cisto preživetje izracunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proucevanega raka (hipoteticen primer, v katerem ne umirajo za drugimi vzroki smrti). Incidenca ali umrljivost preracunani na velikost opazovane populacije. Obicajno je izražena na 100.000 prebivalcev. Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, ce bi bila starostna struktura te populacije enaka kot je v standar- dni populaciji. Uporabljene so tri standardne populacije: svetovno (Segi 1961), evropsko (Doll 1976) in slovensko standardno populacijo (Popis 2002). Kumulativna incidencna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupi- nah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje. Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost po- sameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), ce ne umre prej zaradi drugih vzrokov. Ocena števila novih primerov za tekoce koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vkljuceni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo. 62Incidenca Umrljivost Prevalenca PreživetjeGroba stopnja Starostno standardizirana stopnja Kumulativna stopnja Kumulativno tveganje Ocena incidence PojmovnikDefinicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA: http://www.slora.si/definicije-kazalnikov-in-metod. Število vseh na novo ugotovljenih primerov raka v tocno doloceni populaciji v enem koledarskem letu. Število vseh umrlih za doloceno boleznijo v tocno doloceni populaciji v enem koledarskem letu. Število vseh bolnikov z doloceno boleznijo, ki so bili živi na izbrani datum (po- navadi zadnji dan v letu). Glede na cas, kdaj so zboleli, locimo: .Celotna prevalenca upošteva vse bolnike z rakom, ne glede na to kdaj so zboleli. .Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v tocno dolocenem obdobju pred datumom izracuna. Na primer, v enoletni delni prevalenci so vkljuceni bolniki, ki so zboleli leto pred datumom izracuna ter so na ta datum še živi. Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V porocilu podajamo cisto preživetje izracunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proucevanega raka (hipoteticen primer, v katerem ne umirajo za drugimi vzroki smrti). Incidenca ali umrljivost preracunani na velikost opazovane populacije. Obicajno je izražena na 100.000 prebivalcev. Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, ce bi bila starostna struktura te populacije enaka kot je v standar- dni populaciji. Uporabljene so tri standardne populacije: svetovno (Segi 1961), evropsko (Doll 1976) in slovensko standardno populacijo (Popis 2002). Kumulativna incidencna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupi- nah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje. Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost po- sameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), ce ne umre prej zaradi drugih vzrokov. Ocena števila novih primerov za tekoce koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vkljuceni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo. Glossary63Glossary Definitions of indices and methods are explained in detail on web portal SLORA: http://www.slora.si/en/definicije-kazalnikov-in-metod. Number of all newly diagnosed cancer cases that develop in a defined popula- tion in one calendar year. Number of all patients who died because of certain disease in a defined popu- lation in one calendar year. Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnose we distinguish: .Lifetime prevalence is defined as the number of all persons ever diag- nosed with cancer and being alive at specific time date. .Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation. In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients’ survival from cancer only(all other causes of death excluded). Incidence or mortality calculated per observed population, usually expressed per 100.000 population. Age-standardization tells the crude rate in observed population in case if it´s age structure is the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slove- nian standard population (Census 2002). The cumulative incidence or mortality rate is a special form of direct age stan- dardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk. Cumulative risk is expressed in percentages and interpreted as the risk an indi- vidual would have of developing the disease in question during a certain age period (e.g. up to the age of 74), if no other causes of death were in operation. Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years. Incidence Mortality Prevalence Survival Crude rate Age-standardized rate Cumulative rate Cumulative risk Estimation of incidence 63Glossary Definitions of indices and methods are explained in detail on web portal SLORA: http://www.slora.si/en/definicije-kazalnikov-in-metod. Number of all newly diagnosed cancer cases that develop in a defined popula- tion in one calendar year. Number of all patients who died because of certain disease in a defined popu- lation in one calendar year. Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnose we distinguish: .Lifetime prevalence is defined as the number of all persons ever diag- nosed with cancer and being alive at specific time date. .Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation. In groups of patients, the survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients’ survival from cancer only(all other causes of death excluded). Incidence or mortality calculated per observed population, usually expressed per 100.000 population. Age-standardization tells the crude rate in observed population in case if it´s age structure is the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slove- nian standard population (Census 2002). The cumulative incidence or mortality rate is a special form of direct age stan- dardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk. Cumulative risk is expressed in percentages and interpreted as the risk an indi- vidual would have of developing the disease in question during a certain age period (e.g. up to the age of 74), if no other causes of death were in operation. Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years. Incidence Mortality Prevalence Survival Crude rate Age-standardized rate Cumulative rate Cumulative risk Estimation of incidence POROCILO RR št. 59 REPORT No. 59 Ljubljana 2020 ISSN 1318-5845